Celiac Disease

On this page

Quick Reference

RxDrug of choiceStrict lifelong Gluten-Free Diet (GFD)

AltAlternativesBudesonide (RCD1), Tofacitinib (RCD2), Low FODMAP diet (for persistent non-gluten symptoms)

⊘AvoidHydrolyzed wheat products, gluten-containing grains (wheat, barley, rye)

DxTest of choicetTG-IgA + Total IgA (Screening); Duodenal Biopsy (Confirmation)

ScKey scoreMarsh Classification (Histologic grading)

→When to referDiagnosis confirmation (Gastroenterologist), Dietary planning (Registered Dietitian), Refractory symptoms (Tertiary care)

Celiac disease is an HLA-linked autoimmune enteropathy requiring a lifelong GFD; diagnosis requires positive serology and Marsh $\ge$ 2 histology while on a gluten-containing diet.

Celiac disease is a systemic autoimmune disorder triggered by the ingestion of gluten in genetically predisposed individuals carrying HLA-DQ2 or HLA-DQ8. The condition is characterized by a T-cell mediated immune response that leads to chronic inflammation of the small intestinal mucosa, resulting in villous atrophy, crypt hyperplasia, and subsequent malabsorption. While classically presenting as a pediatric malabsorptive syndrome, the modern clinical phenotype has shifted toward a systemic adult illness often manifesting as iron deficiency anemia, osteoporosis, or asymptomatic seropositivity. The only definitive treatment is a strict, lifelong gluten-free diet (GFD), which aims to achieve complete mucosal healing to prevent long-term complications, including enteropathy-associated T-cell lymphoma (EATL) and small bowel adenocarcinoma.

Overview and Recommendations

Background

•Celiac disease is a systemic immune-mediated enteropathy affecting approximately 1% of the global population, characterized by the triad of genetic predisposition (HLA-DQ2/DQ8), gluten exposure, and an autoimmune response leading to villous atrophy.
•The pathogenic cascade is driven by the enzyme (TG2), which deamidates gliadin peptides, creating high-affinity ligands for HLA-DQ2/DQ8 molecules that activate CD4+ T-helper 1 cells and trigger mucosal destruction.
•The clinical paradigm has shifted from a classic pediatric malabsorption syndrome to a heterogeneous systemic illness; adults now frequently present with non-classical symptoms such as iron deficiency anemia, GERD, or remain entirely asymptomatic (silent celiac disease).
•Histologic staging is standardized via the , ranging from Marsh 0 (normal) to Marsh 3 (total villous atrophy), with Marsh 3 being the hallmark of classic disease.
•Prognostic stakes are high for untreated or non-responsive patients, as persistent villous atrophy (pVA) is a primary predictor of increased mortality and the development of aggressive malignancies like enteropathy-associated T-cell lymphoma (EATL).

Evaluation

•Suspect celiac disease in any patient with chronic diarrhea, abdominal bloating, or unexplained iron deficiency anemia, as well as those with comorbid or other autoimmune conditions.
•Order (tTG-IgA) and total serum IgA as the first-line screening tests; total IgA is mandatory to rule out IgA deficiency, which can cause false-negative tTG-IgA results.
•Order IgG-based tests (e.g., IgG-tTG or IgG-deamidated gliadin peptide) for patients identified with selective IgA deficiency.
•Perform an esophagogastroduodenoscopy (EGD) for histological confirmation in all adults, regardless of serology, unless a 'no-biopsy' approach is indicated (tTG-IgA $\ge$ 10x upper limit of normal and positive EMA-IgA).
•Obtain multiple biopsies (at least 4-6 specimens) from both the duodenal bulb (D1) and the distal duodenum (D2-D3) to account for the patchy nature of mucosal injury and to detect 'ultra-short celiac disease'.
•Assess for extra-intestinal manifestations by screening for osteoporosis (DXA scan) and evaluating for , a pathognomonic pruritic blistering rash.
•Utilize HLA-DQ2/DQ8 genetic testing as a rule-out tool; the absence of these alleles provides a negative predictive value approaching 100%.
•In patients with non-responsive symptoms despite a gluten-free diet, order Video Capsule Endoscopy (VCE) to screen for distal small-bowel villous atrophy or malignancy.
•Escalate to Double-Balloon Enteroscopy (DBE) if VCE identifies suspicious lesions, as DBE allows for targeted biopsies of ulcerative jejunitis or EATL.

Management

•Initiate a strict, lifelong gluten-free diet (GFD) immediately upon diagnosis to normalize gut inflammation and resolve disease-specific antibodies.
•Refer patients to a specialized dietitian to implement a Gluten-Free Food Guide, emphasizing the avoidance of ultra-processed foods and the identification of hidden gluten sources.
•Monitor mucosal recovery via serologic markers (tTG-IgA) and, if indicated, follow-up biopsies to ensure the resolution of villous atrophy.
•Manage persistent gastrointestinal symptoms in patients with confirmed mucosal remission by implementing a moderately low FODMAP diet to reduce fermentable carbohydrate triggers.
•Administer open-capsule 3-9 mg daily for patients with Refractory Celiac Disease Type 1 (RCD1) to manage inflammation.
•Consider 5 mg PO BID for Refractory Celiac Disease Type 2 (RCD2), as JAK inhibition has shown efficacy in achieving clinical remission in this high-mortality phenotype.
•Utilize experimental TG2 inhibitors such as ZED1227 100 mg daily PO in clinical trial settings to attenuate mucosal damage during gluten exposure.
•Employ tight-junction regulators like larazotide acetate 0.5 to 2 mg TID PO for the relief of ongoing symptoms in adults adhering to a GFD.
•Avoid the use of hydrolyzed wheat products, as even low levels of residual gluten can induce mucosal injury and symptomatic relapse.
•Screen first-degree relatives and patients with Type 1 Diabetes proactively, as they carry a significantly elevated risk of developing the disorder.
•Avoid recommending cow's milk-based formula avoidance in high-risk infants, as RCTs show this does not prevent the development of celiac disease.

Board Review — High Yield

•HLA-DQ2/DQ8, Necessary genetic predisposition; absence virtually rules out celiac disease.
•tTG-IgA, First-line screening test; must be paired with total IgA to avoid false negatives in IgA-deficient patients.
•Marsh 3, Total or subtotal villous atrophy, the classic histologic hallmark of celiac disease.
•Dermatitis Herpetiformis, Pathognomonic pruritic blistering rash associated with celiac disease.
•Ultra-Short Celiac Disease, Variant where atrophy is limited to the duodenal bulb (D1), requiring bulbar biopsies for diagnosis.
•EATL, Enteropathy-associated T-cell lymphoma; aggressive malignancy strongly linked to refractory celiac disease.
•Refractory Celiac Disease Type 2, Characterized by aberrant IELs and clonal TCR gamma rearrangement; carries a very poor prognosis.

Deep Dive — Evidence Details

Definition, Classification & Nomenclature

▸Celiac disease is a gluten-induced autoimmune enteropathy requiring genetic susceptibility [9].
▸Refractory Celiac Disease is divided into Type I (normal IELs) and Type II (aberrant IELs), with Type II carrying a worse prognosis [15, 17].
▸The Marsh classification provides the standardized histologic framework for grading mucosal damage from lymphocytic infiltration (Marsh 1) to total villous atrophy (Marsh 3) [1, 20].

HY High Yield: Ultra-short celiac disease (USCD) is limited to the duodenal bulb (D1); failing to biopsy the bulb can lead to a missed diagnosis in these patients [11].

Coeliac disease or celiac disease is a chronic autoimmune disease, mainly affecting the small intestine. It is caused by an abnormal immune system response to gluten, a protein found in wheat and other grains such as bar — Coeliac disease — Coeliac disease or celiac disease is a chronic autoimmune disease, mainly affecting the small intestine. It is caused by an abnormal immune system res...Wikipedia ↗

Celiac disease is a gluten-induced enteropathy that develops in genetically susceptible individuals upon the consumption of cereal gluten proteins ^[9]^D5. It is a complex autoimmune disorder characterized by a maladapted immune response involving CD4+ T cells, cytotoxic CD8+ T cells, and B cells, which results in targeted tissue damage to the small intestinal mucosa ^[9]^D5.

Also Called / Synonyms: Celiac sprue, coeliac disease (CD), gluten-sensitive enteropathy, gluten-induced enteropathy.

Clinical Classifications and Variants

Clinicians categorize celiac disease based on the extent of mucosal involvement, the presence of serologic markers, and the response to dietary intervention. These distinctions are critical because they dictate the biopsy strategy and the expected trajectory of mucosal healing ^[1]^A1c^[11]^B2b.

Ultra-Short Celiac Disease (USCD): A variant where villous atrophy is limited strictly to the duodenal bulb (D1) ^[11]^B2b. This phenotype is clinically significant because standard biopsies of the second part of the duodenum (D2) may yield false negatives ^[11]^B2b.
Seronegative Enteropathy: A state where patients exhibit classic histological features of celiac disease (e.g., villous atrophy) but maintain negative results on standard serologic tests ^[3]^A1c.
Refractory Celiac Disease (RCD): A rare, severe condition where the intestinal mucosa fails to heal despite strict adherence to a gluten-free diet (GFD) ^[15]^D5^[17]^C4.

Type	Key Distinguishing Feature	Associated Marker/Subtype
RCD Type I	Normal intraepithelial lymphocyte (IEL) phenotype	Normal IEL phenotype ^[15]^D5^[17]^C4
RCD Type II	Abnormal IEL phenotype; higher malignancy risk	Aberrant IEL phenotype or clonal TCR gamma gene rearrangement ^[15]^D5^[17]^C4
NCGS	Gluten-triggered symptoms without autoimmunity or atrophy	No serologic markers or intestinal damage ^[10]^D5^[23]^C4

Histologic Grading (Marsh Classification)

The Marsh classification is the gold-standard semiquantitative method used to grade duodenal biopsies ^[1]^A1c^[20]^B3b. It allows clinicians to track disease activity and the efficacy of a GFD by measuring the progression from normal mucosa to total villous atrophy ^[1]^A1c^[20]^B3b.

Marsh 0: Normal mucosa.
Marsh 1: Lymphocytic infiltration (increased IELs) without architectural distortion ^[1]^A1c^[19]^B2b.
Marsh 2: Lymphocytic infiltration with crypt hyperplasia ^[1]^A1c^[19]^B2b.
Marsh 3: Partial to total villous atrophy (subdivided into 3a, 3b, and 3c based on the degree of atrophy) ^[1]^A1c^[31]^B3b.

Celiac disease is a systemic disorder affecting approximately 1% of the global population, with manifestations extending beyond the gut to include psychological, psychiatric, and organic brain dysfunction ^[40]^D5.

Pearl: Celiac disease is defined by the triad of genetic predisposition, gluten exposure, and a specific autoimmune response leading to villous atrophy, with the Marsh classification serving as the primary tool for histologic staging ^[1]^A1c^[9]^D5.

Pathophysiology & Mechanism

▸Celiac disease requires the triad of gluten ingestion, HLA-DQ2/DQ8 genetic predisposition, and TG2-mediated deamidation of gliadin peptides.
▸The mechanism involves both an innate breach of the intestinal barrier (zonulin-mediated) and an adaptive T-cell response leading to villous atrophy.
▸Systemic manifestations, such as osteoporosis, can be driven by specific autoantibodies (e.g., against osteoprotegerin) independent of mucosal healing [44].

HY High Yield: HLA-DQ2 and HLA-DQ8 are necessary but not sufficient for disease development; their absence virtually excludes the diagnosis [62].

Chronic immune-mediated mucosal injury drives a cycle of villous atrophy, crypt hyperplasia, and systemic inflammation that culminates in malabsorption and extraintestinal manifestations ^[46]^D5^[48]^D5. This process requires the convergence of a specific dietary trigger, a permissive genetic background, and an environmental milieu that facilitates the breach of the intestinal barrier.

The Pathogenic Cascade

The transition from gluten ingestion to mucosal destruction occurs through a precise sequence of luminal and cellular events:

Gluten Ingestion and Partial Digestion: Dietary gluten, specifically the proline- and glutamine-rich proteins gliadin and glutenin, resists complete hydrolysis by gastric and pancreatic enzymes ^[46]^D5^[56]^C4.
Intestinal Barrier Breach: Gliadin peptides increase intestinal permeability by modulating the tight junction protein zonulin and inducing direct toxic effects on the epithelium ^[53]^D5^[56]^C4.
Enzymatic Modification: Once in the lamina propria, the enzyme tissue transglutaminase 2 (TG2) deamidates glutamine residues in gliadin peptides into negatively charged glutamic acid ^[46]^D5^[74]^C4.
Antigen Presentation: These deamidated peptides have a significantly higher affinity for the binding grooves of HLA-DQ2 or HLA-DQ8 molecules on antigen-presenting cells ^[46]^D5^[62]^D5.
T-Cell Activation: The HLA-peptide complex activates gluten-specific CD4+ T-helper 1 cells, which secrete pro-inflammatory cytokines, including IFN-gamma and TNF-alpha ^[46]^D5^[74]^C4.
B-Cell Recruitment and Autoantibody Production: Gluten-specific T cells provide help to TG2-specific B cells within the gut-associated lymphoid tissue (GALT), specifically in Peyer's patches, leading to the production of anti-TG2, anti-deamidated gliadin peptide (DGP), and anti-endomysial antibodies ^[46]^D5^[49]^C4.
Mucosal Destruction: The combined effect of innate immune responses and adaptive T-cell cytotoxicity leads to the recruitment of neutrophils and the destruction of enterocytes, resulting in the characteristic villous atrophy ^[24]^C4^[46]^D5.

Genetic and Environmental Susceptibility

Genetic predisposition is a mandatory requirement, though not a sufficient cause, for the development of the disease. The strongest association exists with the HLA-DQ2 and HLA-DQ8 haplotypes; the absence of these molecules provides a negative predictive value for celiac disease approaching 100% ^[62]^D5. Beyond the HLA region, non-HLA polymorphisms, such as those in the 5'UTR of XPO1, influence the inflammatory environment of the intestinal epithelium ^[54]^C4.

Environmental modifiers act as catalysts for the onset of autoimmunity in genetically at-risk individuals:

Microbiome Dysbiosis: Alterations in the duodenal microbiota and a reduced capacity of microbial-derived peptidases to hydrolyze gluten are associated with increased disease risk ^[36]^A1a^[51]^C4.
Early Life Exposure: Systemic antibiotic use in the first year of life is linked to an increased risk of diagnosis, likely via disruption of the developing gut microbiota ^[52]^B2b.
Intestinal Permeability: Pre-existing barrier defects or the influence of non-gluten dietary triggers may lower the threshold for gluten-induced inflammation ^[50]^D5^[53]^D5.

Systemic and Extra-Intestinal Mechanisms

While the primary lesion is intestinal, the disease is a systemic immune illness ^[48]^D5. Circulating immune complexes and cytokines can trigger remote organ damage. For example, some patients develop neutralizing autoantibodies against osteoprotegerin, which blocks the inhibitory effect on RANK signaling, leading to high-turnover osteoporosis that may be refractory to a gluten-free diet ^[44]^C4. Neurologic manifestations also occur, reflecting the systemic nature of the immune activation ^[73]^D5.

Comparative Pathogenesis of Gluten-Related Disorders

It is critical to distinguish the autoimmune mechanism of celiac disease from other gluten-related responses.

Feature	Celiac Disease	Non-Celiac Gluten Sensitivity (NCGS)
Mechanism	T-cell mediated autoimmunity (HLA-DQ2/8) ^[46]^D5	Innate immune response / non-immunological ^[10]^D5^[66]^D5
Key Mediator	TG2 / CD4+ T cells ^[46]^D5	Likely non-TG2 mediated ^[69]^B2b	IgE-mediated ^[55]^C4
Histology	Villous atrophy / Crypt hyperplasia ^[24]^C4	Normal or mild inflammation ^[69]^B2b	Eosinophilic infiltration ^[55]^C4
Serology	Anti-TG2 / Anti-EMA positive ^[46]^D5	Negative for CD markers ^[10]^D5	Wheat-specific IgE positive ^[55]^C4

Pearl: The central pathogenic event is the TG2-mediated deamidation of gliadin, which creates high-affinity ligands for HLA-DQ2/DQ8, triggering a CD4+ T-cell driven autoimmune cascade ^[46]^D5^[49]^C4.

Comparative Pathogenesis of Gluten-Related Disorders

Feature	Celiac Disease	Non-Celiac Gluten Sensitivity (NCGS)	Wheat Allergy
Mechanism	T-cell mediated autoimmunity (HLA-DQ2/8) ^[46]^D5	Innate immune response / non-immunological ^[10]^D5^[66]^D5	IgE-mediated ^[55]^C4
Key Mediator	TG2 / CD4+ T cells ^[46]^D5	Likely non-TG2 mediated ^[69]^B2b	IgE-mediated ^[55]^C4
Histology	Villous atrophy / Crypt hyperplasia ^[24]^C4	Normal or mild inflammation ^[69]^B2b	Eosinophilic infiltration ^[55]^C4
Serology	Anti-TG2 / Anti-EMA positive ^[46]^D5	Negative for CD markers ^[10]^D5	Wheat-specific IgE positive ^[55]^C4

Epidemiology, Etiology & Risk Factors

▸Global prevalence ranges from 0.7% to 2.9%, with a real increase in incidence over recent decades [114, 110].
▸HLA-DQ2 and HLA-DQ8 are necessary genetic prerequisites, though they are present in 40% of the healthy population [87].
▸Strong associations exist with other autoimmune disorders, particularly IBD (RR 3.9) and Type 1 Diabetes [86, 108].

HY High Yield: While women are diagnosed at a 2:1 ratio compared to men, screening data suggests the actual prevalence is similar across sexes, indicating a diagnostic bias [100, 119].

Global prevalence of celiac disease ranges primarily between 0.7% and 2.9% in the general population ^[114]^D5. While historically viewed as a disorder concentrated in Northern Europe and Australasia, it is now recognized as equally common in North America and the Middle East ^[109]^B2a. Prevalence remains lower in East Asia and Sub-Saharan Africa ^[109]^B2a.

Demographic Distribution and Temporal Trends

Incidence is increasing worldwide, driven by both improved diagnostic awareness and a real increase in the occurrence of the disorder ^[81]^A1c^[88]^B2a^[110]^D5. This rise is independent of improved detection rates, though the exact environmental drivers remain unknown ^[110]^D5.

Sex-based differences are evident in clinical diagnosis, where women are diagnosed more frequently than men at a ratio of 2:1 ^[119]^B3b. However, in undiagnosed populations, the prevalence of the disease does not differ significantly between sexes ^[100]^B2a. Age of onset is highly variable; while classically associated with early childhood, the disease can arise at any age ^[71]^D5. A specific phenotype, ultra-short celiac disease (USCD), typically presents in younger patients (median age 27 years) compared to conventional celiac disease (median age 38 years) ^[105]^B3b.

Etiology and Risk Factors

Celiac disease is an immune-mediated reaction to dietary gluten triggered in genetically predisposed individuals ^[81]^A1c^[111]^D5. The strongest non-modifiable risk factor is the presence of HLA-DQ2 or HLA-DQ8 heterodimers ^[82]^A1b^[113]^D5. While approximately 40% of the general population carries these alleles, most do not develop the disease, indicating that genetic susceptibility is necessary but not sufficient ^[87]^B3b.

First-degree relatives (FDRs) carry a significantly elevated risk of developing the disorder ^[91]^B2a. In infants with high genetic risk and an affected FDR, the timing of gluten introduction has been studied as a modifiable trigger, though randomized trials have not proven these strategies successful in reducing overall disease development ^[82]^A1b^[83]^A1b^[110]^D5.

Associated Comorbidities

Patients with other autoimmune conditions are at a higher risk of celiac disease, necessitating proactive screening in specific groups ^[111]^D5.

Associated Condition	Risk / Prevalence	Evidence Level
Inflammatory Bowel Disease (IBD)	RR 3.9 ^[86]^B2a / HR 4.0 ^[97]^B2b	2a/2b
Type 1 Diabetes (T1D)	Pooled seroprevalence varies globally ^[108]^B2a	2a
Iron Deficiency Anemia (IDA)	High prevalence (screening recommended) ^[85]^B2a	2a
Irritable Bowel Syndrome (IBS)	Overlapping symptoms; screening recommended ^[90]^B2a^[92]^B2a^[111]^D5	2a
Liver Disease	Increased prevalence in cryptogenic cirrhosis/hypertransaminasemia ^[89]^B2a	2a

Risk Factor Summary

Factor	OR/RR/HR	Evidence Level
HLA-DQ2/DQ8	Necessary (but not sufficient)	1b
First-Degree Relative	High Risk	2a
IBD	RR 3.9	2a
T1D	Increased Risk	2a

Pearl: Celiac disease affects approximately 1% of the global population, with a significant diagnostic gap where women are diagnosed twice as often as men despite similar prevalence ^[100]^B2a^[114]^D5^[119]^B3b.

Clinical Presentation

▸Presentation has shifted from classic malabsorption to non-classical and silent phenotypes [48, 140].
▸Iron deficiency anemia is a common atypical presentation and often correlates with more severe villous atrophy [85, 142].
▸Extraintestinal manifestations include dermatitis herpetiformis and associations with other autoimmune disorders like Type 1 Diabetes [138, 149].

HY High Yield: Do not rule out celiac disease in patients with a high BMI; an increasing number of pediatric and adult patients present with normal or obese phenotypes [124].

Phenotypic expression of celiac disease has evolved from a pediatric malabsorption syndrome to a systemic immune illness affecting all ages ^[48]^D5. While classic symptoms remain common, a significant proportion of patients present with extraintestinal manifestations or remain entirely asymptomatic until screened ^[48]^D5^[110]^D5.

Presenting Symptoms

Patients typically present with a heterogeneous array of symptoms that may develop acutely after episodic gluten exposure or progress insidiously over months to years ^[48]^D5. Gastrointestinal distress is the most frequent driver of clinical visits, often manifesting as abdominal bloating, belching, and distention ^[41]^A1c. These symptoms are frequently debilitating and significantly impair quality of life and work attendance ^[41]^A1c.

Chronic diarrhea is a hallmark of the classic phenotype, often driven by malabsorption or bile acid diarrhea ^[133]^D5. In the latter, malabsorption of bile acids in the damaged proximal small bowel leads to their delivery into the colon, stimulating water secretion ^[133]^D5. Conversely, many adults present with non-classical symptoms, such as gastroesophageal reflux disease (GERD), with 30.1% of patients reporting moderate to severe heartburn and regurgitation at diagnosis ^[141]^B2b.

Physical Examination and Systemic Findings

Examination findings vary by age and disease severity. In pediatric populations, malabsorption traditionally manifests as failure to thrive, malnutrition, and underweight status ^[124]^B2a. However, recent data indicate an increasing prevalence of with normal or high BMI, which can lead to delayed diagnosis ^[124]^B2a.

Systemic findings often reflect chronic nutrient deficiencies. Iron deficiency anemia (IDA) is a frequent mode of presentation and is often associated with more severe villous atrophy than patients presenting with diarrhea ^[85]^B2a^[142]^B3b. Dermatologic examination may reveal , a pathognomonic pruritic blistering rash ^[138]^B2b.

Phenotypic Variants

Celiac disease is characterized by high heterogeneity, ranging from the classic malabsorptive state to completely silent forms ^[110]^D5^[140]^B3b.

Variant	Key Features	Frequency
Classic	Diarrhea, weight loss, steatorrhea, failure to thrive (pediatrics) ^[48]^D5^[124]^B2a	Decreasing ^[140]^B3b
Non-Classic	Anemia, osteoporosis, GERD, or isolated bloating/distention ^[48]^D5^[85]^B2a^[141]^B2b	Increasing ^[140]^B3b
Silent	Asymptomatic; detected via serology or biopsy during screening ^[48]^D5^[110]^D5	Common ^[48]^D5
Seronegative	Histologic enteropathy with negative standard serologic markers ^[3]^A1c	Rare ^[3]^A1c

Red Flags and Atypical Presentations

Certain presentations require urgent investigation due to the risk of malignancy or severe complications. Intestinal obstruction or gastrointestinal hemorrhage may signal ulcerative jejunitis, a rare complication involving mucosal ulceration past the angle of Treitz ^[134]^C4.

Patients presenting with lymphadenopathy or systemic B-symptoms should be evaluated for enteropathy-associated T-cell lymphoma or ^[143]^B3b. Additionally, the presence of autoimmune liver disease, such as , may coexist with celiac disease, often manifesting as elevated aminotransferase activity ^[144]^B3b.

Atypical and Mimicking Presentations

Clinicians must distinguish celiac disease from other gluten-related disorders and autoimmune overlaps. Non-celiac gluten sensitivity (NCGS) presents with similar GI symptoms but lacks the characteristic villous atrophy and serology of celiac disease ^[10]^D5^[132]^B3b.

Celiac disease also frequently clusters with other autoimmune conditions. It may be part of autoimmune polyglandular syndrome type 4, occurring alongside type 1 diabetes, autoimmune hepatitis, and immune thrombocytopenia ^[149]^C4. Other associations include autoimmune atrophic gastritis, which may present as and neurologic symptoms ^[145]^C4.

Pearl: The clinical spectrum of celiac disease has shifted from classic pediatric malabsorption to a systemic adult illness where iron deficiency anemia or asymptomatic serology are now frequent primary findings ^[48]^D5^[85]^B2a^[140]^B3b.

Diagnosis & Workup

▸tTG-IgA is the first-line screening test, but must be paired with total IgA to rule out IgA deficiency.
▸The gold standard is duodenal biopsy showing villous atrophy, requiring at least 4-6 samples from both the bulb and distal duodenum to detect patchy or ultra-short disease.
▸A no-biopsy approach is emerging for adults with tTG-IgA $\ge$ 10x ULN, though it remains a point of guideline debate.

Dx Diagnostic Essentials: Gold Standard: Histopathologic examination of multiple duodenal biopsies demonstrating villous atrophy (Marsh grade $\ge$ 2) while on a gluten-containing diet.

HY High Yield: Always order Total IgA with tTG-IgA; a negative tTG in the setting of IgA deficiency is a false negative, not a rule-out for celiac disease [1].

Establishing a diagnosis of celiac disease (CD) requires a combination of serological screening and histological confirmation while the patient is consuming a gluten-containing diet ^[1]^A1c^[110]^D5^[164]^A1c. Because symptoms often overlap with other functional disorders, such as irritable bowel syndrome (IBS), a structured diagnostic hierarchy is essential to avoid misdiagnosis ^[90]^B2a^[92]^B2a^[169]^D5.

Laboratory Studies

Serology serves as the primary screening tool due to its high sensitivity and specificity ^[1]^A1c^[81]^A1c. The IgA anti-tissue transglutaminase (tTG-IgA) antibody is the preferred first-line test ^[1]^A1c^[164]^A1c. However, because IgA deficiency is more common in patients with CD, total serum IgA must be measured concurrently to avoid false-negative results ^[1]^A1c^[81]^A1c. In patients with IgA deficiency, IgG-based tests (e.g., IgG-tTG or IgG-deamidated gliadin peptide) are indicated ^[1]^A1c^[113]^D5.

Test	Finding	Clinical Utility	Sensitivity	Specificity
tTG-IgA	Elevated	First-line screening ^[1]^A1c^[164]^A1c	High	High
EMA-IgA	Positive	Confirmatory serology ^[1]^A1c^[81]^A1c	Very High	Very High
Total IgA	Low	Identifies IgA deficiency ^[1]^A1c	N/A	N/A
HLA-DQ2/DQ8	Positive	Rule-out test (high NPV) ^[113]^D5	Low	High
DGP-IgG	Elevated	Used in IgA deficiency/children ^[113]^D5	Moderate	High

Genetic testing for HLA-DQ2 and HLA-DQ8 is not used for primary diagnosis but is highly effective for ruling out CD; the absence of these alleles makes a diagnosis of CD extremely unlikely ^[113]^D5^[168]^B2b.

Gold-Standard Test: Duodenal Biopsy

<div class="diagnostic_essential"> **Gold Standard:** Histopathologic examination of multiple duodenal biopsies demonstrating villous atrophy (Marsh grade $\ge$ 2) while on a gluten-containing diet. </div>

Biopsy remains the definitive requirement for most adult patients to confirm the diagnosis ^[1]^A1c^[164]^A1c. The hallmark findings include villous atrophy, crypt hyperplasia, and increased intraepithelial lymphocytes (IELs) ^[1]^A1c^[171]^C4. The Marsh classification is used to grade these changes, with Marsh 3 (total or subtotal villous atrophy) being the classic diagnostic threshold ^[1]^A1c^[94]^B2b.

To account for the patchy nature of mucosal injury, a multiple-biopsy strategy is mandatory ^[158]^B2b. Guidelines recommend obtaining at least 4 to 6 specimens, including samples from the duodenal bulb (D1) and the distal duodenum (D2-D3) ^[1]^A1c^[121]^B3b. This is critical because "ultra-short celiac disease" may present with atrophy limited solely to the duodenal bulb ^[105]^B3b^[112]^D5.

Endoscopic and Imaging Modalities

Esophagogastroduodenoscopy (EGD) is the vehicle for biopsy. While the mucosa often appears normal, specific signs such as scalloping of the folds, a mosaic pattern, or a "cracked-earth" appearance can prompt a high suspicion of villous atrophy ^[103]^B2b^[155]^A1a. Advanced techniques like chromo-zoom endoscopy or confocal endomicroscopy can improve the detection of atrophy but do not replace the need for histology ^[154]^B3b^[33]^C4.

Cross-sectional imaging and enteroscopy are reserved for complicated celiac disease (CCD) or non-responsive cases. Wireless capsule endoscopy (WCE) and double-balloon enteroscopy (DBE) are used to screen for small-bowel malignancies, such as T-cell lymphoma, or to evaluate persistent symptoms despite a gluten-free diet ^[156]^A1a^[170]^B2b^[175]^C4.

Diagnostic Algorithm

Initial Screening: Order tTG-IgA and Total IgA ^[1]^A1c^[164]^A1c.
Serology Interpretation:
- If tTG-IgA is $\ge$ 10x the upper limit of normal (ULN) in symptomatic adults and EMA-IgA is positive, a "no-biopsy" approach may be considered in specific clinical contexts, though biopsy remains the standard in most guidelines ^[84]^A1a^[161]^D5^[164]^A1c.
- If tTG-IgA is positive but < 10x ULN, proceed to EGD with multiple biopsies ^[1]^A1c^[184]^B3b.
- If tTG-IgA is negative but Total IgA is low, order IgG-based serology ^[1]^A1c.
Histologic Confirmation: Perform EGD with $\ge$ 4 biopsies (bulb and distal duodenum) ^[1]^A1c^[121]^B3b.
Final Diagnosis: Confirm if histology shows Marsh $\ge$ 2 and serology is positive ^[1]^A1c^[164]^A1c.
Equivocal Cases: If serology is negative but atrophy is present (seronegative villous atrophy), evaluate for other causes or use HLA testing to support a CD diagnosis ^[112]^D5^[163]^B2b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
No-Biopsy Approach	Acceptable if tTG-IgA $\ge$ 10x ULN and EMA positive ^[84]^A1a	Biopsy required for all adults to confirm diagnosis ^[164]^A1c	Moderate	Potential to reduce invasive procedures in high-titer patients
Biopsy Number	$\ge$ 4-6 biopsies required to avoid missing patchy lesions ^[1]^A1c^[121]^B3b	Fewer biopsies may suffice in classic presentations ^[31]^B3b	High	Standard of care favors multiple samples to increase yield

Pearl: The diagnosis of celiac disease requires the triad of positive serology (tTG-IgA), histological evidence of villous atrophy (Marsh $\ge$ 2), and a gluten-containing diet; missing any of these can lead to significant diagnostic error ^[1]^A1c^[164]^A1c.

Severity, Staging & Risk Stratification

▸The Marsh-Oberhuber system is the gold standard for staging, but mucosal severity (Marsh grade) does not always correlate with clinical symptom severity [205].
▸Persistent villous atrophy (pVA) is a high-risk marker for increased mortality and long-term complications [94].
▸Accurate severity staging requires multiple biopsies to account for patchy atrophy and ultra-short celiac disease (USCD) [11, 158].

HY High Yield: Ultra-short celiac disease (USCD) is characterized by villous atrophy limited to the duodenal bulb (D1); failing to biopsy the bulb can lead to understaging or missed diagnosis [11].

Histological grading remains the primary determinant of disease severity, though clinical outcomes often decouple from mucosal morphology. The Marsh-Oberhuber classification is the most widely utilized semiquantitative system to stage mucosal damage, ranging from Marsh 0 (normal mucosa) to Marsh 3 (total villous atrophy) ^[194]^D5. While Marsh 3 is the hallmark of classic celiac disease, patients with mild enteropathy (Marsh <3) may still exhibit significant clinical and laboratory abnormalities, indicating that mucosal severity does not always correlate linearly with systemic disease burden ^[205]^B3b.

Histological Severity and Morphometry

Quantitative histology provides a more objective assessment of severity than semiquantitative grading by measuring specific architectural parameters ^[194]^D5. The villus height to crypt depth (Vh:Cd) ratio is a critical metric for assessing mucosal injury and response to therapy ^[152]^A1b^[194]^D5.

Morphometric evaluation allows for the detection of subtle changes that the Marsh system may miss, particularly during the recovery phase following the introduction of a gluten-free diet (GFD) ^[20]^B3b. However, the distribution of these lesions is often non-uniform. Villous atrophy can be patchy, and "ultra-short celiac disease" (USCD) occurs when atrophy is limited strictly to the duodenal bulb (D1) ^[11]^B2b^[200]^B2b. To avoid understaging severity, multiple biopsies from both the bulb and the second part of the duodenum are required ^[11]^B2b^[158]^B2b.

Prognostic Scoring and Risk Stratification

Persistent villous atrophy (pVA), defined as Marsh $\ge$3a despite adherence to a GFD, serves as a major prognostic marker for long-term complications ^[94]^B2b. pVA is associated with an increased risk of mortality and the development of associated comorbidities ^[94]^B2b.

Risk stratification for the development of celiac disease in high-risk populations, such as first-degree relatives, now utilizes weighted genetic risk scores. Combining HLA-DQ2/DQ8 status with non-HLA single nucleotide polymorphisms (SNPs) improves the predictive accuracy of disease onset compared to HLA testing alone ^[87]^B3b. In pediatric populations, multivariable Cox proportional hazards models are used to create individualized risk scores to determine the optimal frequency of screening ^[193]^B2b.

Disease Activity and Symptom Indices

Because histological recovery often lags behind symptomatic improvement, validated patient-reported outcome measures (PROMs) are used to quantify disease activity ^[6]^B2a^[107]^D5.

Tool	Focus	Clinical Application
Celiac Symptom Index (CSI)	and general health symptoms	Assessing symptomatic burden and response to adjunctive therapies ^[152]^A1b^[206]^C4
CDLIFE	Pediatric quality of life	Evaluating family experiences and youth-specific psychosocial impact ^[195]^C4
GFD Adherence Tool	Dietary compliance	Validating GFD adherence against serology (IgA-tTG) and urinary peptides ^[196]^B2b

Complication-Based Risk Stratification

Severity is further stratified by the presence of extra-intestinal manifestations and associated autoimmune conditions. Patients with biopsy-verified celiac disease exhibit a significantly increased risk of hepatobiliary and pancreatic complications ^[202]^B2b^[203]^B2b^[207]^B2b. Specifically, celiac disease is associated with an increased risk of acute hepatitis (HR 5.21, 95% CI 1.88-14.40) and chronic hepatitis (HR 5.84, 95% CI 2.89-11.79) ^[207]^B2b.

Pearl: While the Marsh classification stages mucosal damage, persistent villous atrophy (Marsh $\ge$3a) despite a GFD is the most critical histological predictor of long-term complications and increased mortality ^[94]^B2b.

Acute Management

▸Acute gluten exposure in CeD patients can be distinguished from NCGS by plasma IL-2 levels [226].
▸ZED1227 (100 mg daily) is a potent TG2 inhibitor that prevents gluten-induced mucosal damage and inflammation [152, 234].
▸Multispecies probiotics in children can accelerate BMI-Z score recovery during the initial phase of GFD [239].

Rx Drug of Choice: Strict Gluten-Free Diet (GFD) is the only definitive treatment for acute and chronic celiac disease [219].

! Warning: Avoid hydrolyzed wheat products; residual gluten levels as low as 2480 ppm can trigger symptomatic and serologic responses [228].

Immediate clinical priority in acute gluten exposure focuses on the mitigation of mucosal injury and the resolution of symptoms. While celiac disease typically presents as a chronic condition, acute ingestion of gluten in treated patients can trigger rapid-onset symptoms including pain, bloating, nausea, and fatigue ^[226]^A1b (1b).

Step 1: Initial Assessment and Symptom Stratification

Clinicians must first distinguish between acute gluten-induced symptoms and persistent symptoms occurring despite a strict gluten-free diet (GFD). Acute exposure is characterized by a temporal relationship between gluten ingestion and the onset of symptoms, often accompanied by a rise in plasma interleukin-2 (IL-2) levels, which helps distinguish celiac disease (CeD) from non-celiac gluten sensitivity (NCGS) ^[226]^A1b (1b). Patients should be stratified by severity: mild symptoms (bloating, nausea) are managed conservatively, while severe presentations requiring hospitalization (e.g., severe malabsorption or suspected refractory states) require inpatient stabilization.

Step 2: First-Line Intervention

Strict cessation of all gluten intake is the only definitive acute intervention to stop the inflammatory cascade ^[219]^A1b (1b). For patients experiencing acute symptoms, supportive care is the standard of care. While various enzymatic therapies have been investigated to degrade gluten in the lumen, their clinical utility in acute settings remains limited.

Step 3: Adjunctive and Investigational Pharmacotherapy

For patients with persistent symptoms or those at high risk of mucosal damage during known exposure, several targeted therapies have been evaluated in clinical trials, though none are currently FDA-approved for acute rescue:

TG2 Inhibition: ZED1227, a selective oral transglutaminase 2 inhibitor, has demonstrated the ability to attenuate gluten-induced mucosal damage (measured by villus height to crypt depth ratio) and reduce the Celiac Symptom Index score ^[152]^A1b (1b). Transcriptomic analysis confirms it prevents gluten-induced intestinal inflammation ^[234]^A1b (1b).
Tight-Junction Regulation: Larazotide acetate acts as a tight-junction regulator to prevent the paracellular transport of gluten peptides into the lamina propria ^[186]^A1b (1b). In trials, it has been used to relieve ongoing symptoms in adults on a GFD ^[131]^A1b (1b).
Enzymatic Degradation: Latiglutenase (IMGX003) is designed to protect the mucosa and attenuate symptom severity during gluten challenge ^[217]^A1b (1b), although earlier phase 2 studies showed no significant difference from placebo in reducing villous atrophy ^[221]^A1b (1b).

Step 4: Monitoring and Recovery

Recovery is monitored via serologic markers and, if indicated, histological assessment. The biopsy proteome score is emerging as a more objective measure of intestinal remodeling and mucosal damage than traditional histology in response to gluten challenge ^[227]^B2b (2b). In pediatric populations, the addition of multispecies to a GFD has been shown to accelerate clinical and laboratory recovery, specifically resulting in a significantly higher and faster increase in BMI-Z scores compared to GFD alone ^[239]^A1b (1b).

Step 5: Transition to Long-Term Maintenance

Once acute symptoms resolve, the focus shifts to preventing recurrence. This includes the use of portable gluten sensors (e.g., Nima) to improve GFD adherence and quality of life ^[231]^A1b (1b). For patients who remain symptomatic despite mucosal healing, a moderately low FODMAP diet may be implemented to reduce functional gastrointestinal symptoms ^[229]^A1b (1b).

Drug / Modality Comparison Table

Option	Indication	Dose/Specifics	Key Trial	Outcome	Evidence Level
ZED1227	Mucosal protection	100 mg daily PO	NEJM ^[152]^A1b	Attenuated mucosal damage	1b
Larazotide acetate	Persistent symptoms	0.5 to 2 mg TID PO	Gastroenterology ^[131]^A1b	Reduced symptom scores	1b
Latiglutenase	Symptom attenuation	1200 mg PO	Gastroenterology ^[217]^A1b	Attenuated symptom severity	1b
Low FODMAP	Non-gluten symptoms	Moderate restriction	CGH ^[229]^A1b	Reduced persistent symptoms	1b

Dosing Table

Drug	Starting dose	Target / max dose	Renal adjustment	Hepatic adjustment	Key monitoring
ZED1227	100 mg daily	100 mg daily	Not reported	Not reported	Villus height:crypt depth
Larazotide acetate	0.5 mg TID	2 mg TID	Not reported	Not reported	GSRS score
Latiglutenase	1200 mg	1200 mg	Not reported	Not reported	Mucosal morphometry

What NOT to Do

Do NOT use hydrolyzed wheat products as a substitute for a GFD; baked goods with residual gluten (even at 2480 ppm) can induce symptoms and increase serologic markers in CeD patients ^[228]^A1b (1b).
Do NOT rely on self-reported gluten sensitivity to diagnose CeD; many patients with NCGS are actually reacting to fructans rather than gluten ^[222]^A1b (1b).

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Efficacy of Latiglutenase	Gastroenterology 2022, protects mucosa and attenuates symptoms ^[217]^A1b	Gastroenterology 2016, no difference from placebo in villous atrophy or symptoms ^[221]^A1b	Moderate	Conflicting trial data suggests efficacy may be dose-dependent or population-specific.

Pearl: The primary acute of gluten exposure is the immediate cessation of gluten intake; while TG2 inhibitors like ZED1227 show promise in attenuating mucosal damage ^[152]^A1b, strict GFD remains the only definitive therapy.**

Long-term & Definitive Medical Management

▸Strict lifelong GFD is the only definitive therapy to achieve mucosal healing and prevent complications [12, 216].
▸Persistent symptoms despite GFD often stem from non-gluten triggers, specifically FODMAPs or comorbid conditions like microscopic colitis [229, 248].
▸Refractory Celiac Disease Type 2 (RCD2) requires aggressive management, with JAK inhibitors like tofacitinib showing promise where steroids fail [249].

Rx Drug of Choice: Strict lifelong Gluten-Free Diet (GFD) is the first-line and only definitive treatment for all patients with celiac disease [216].

! Warning: Do not assume mucosal healing based on symptom resolution alone; histological or serologic confirmation is required to ensure the prevention of long-term complications [246].

Strict lifelong adherence to a gluten-free diet (GFD) remains the only definitive treatment for celiac disease, as it is the only intervention proven to normalize gut inflammation and disease-specific antibodies ^[12]^C4^[216]^A1b. While the GFD is the cornerstone of therapy, the clinical objective extends beyond symptom relief to achieving complete mucosal healing, which is critical for the prevention of long-term complications ^[246]^B2b.

Step 1: Implementation of the Gluten-Free Diet

Initiate a strict GFD immediately upon diagnosis ^[216]^A1b. For asymptomatic patients with serologic markers of celiac disease, a GFD is indicated as it improves the ratio of small-bowel mucosal villous height to crypt depth and improves physiologic well-being ^[223]^A1b (1b).

To optimize adherence and nutritional quality, clinicians should employ the following strategies:

Dietary Education: Utilize structured tools, such as a Gluten-Free Food Guide, to increase dietary variety and reduce the intake of ultra-processed foods, particularly in pediatric populations ^[35]^A1b (1b).
Adherence Support: Implement interactive online interventions to improve GFD adherence, which has been shown to enhance patient knowledge and quality of life ^[224]^B2b (2b).
Monitoring Tools: Consider the use of portable gluten sensor devices to help patients identify hidden gluten and improve overall quality of life ^[231]^A1b (1b).

Step 2: of Persistent Symptoms

Persistent symptoms occur frequently despite a GFD. Clinicians must first distinguish between gluten-induced injury and non-gluten triggers.

Evaluate for non-gluten triggers if the patient is in serologic and mucosal remission but remains symptomatic ^[229]^A1b.

FODMAPs: A moderately low FODMAP diet significantly reduces symptoms in treated celiac patients with ongoing symptoms ^[229]^A1b (1b). This is supported by evidence that fructans, rather than gluten, induce symptoms in those with non-celiac gluten sensitivity ^[222]^A1b (1b).
Hereditary Alpha-Tryptasemia (HT): Screen for HT in patients with persistent IBS-like symptoms, as increased copy numbers of TPSAB1 are associated with ongoing symptoms despite GFD ^[135]^B2b (2b).
Comorbidities: Assess for associated conditions such as , which occurs at a 70-fold increased risk in celiac patients compared to the general population (SMR 72.39, 95% CI 52.52-95.36) ^[248]^B3b (3b).

Step 3: Adjunctive and Experimental Pharmacotherapy

Currently, no non-dietary therapy is FDA-approved for the general maintenance of celiac disease. However, several agents are under investigation to manage inadvertent exposure or enhance mucosal healing.

Tight Junction Regulation: Larazotide acetate, a tight-junction regulator, has been studied to relieve ongoing symptoms in adults on a GFD ^[131]^A1b (1b) and to prevent the activation of celiac disease during gluten challenge ^[186]^A1b (1b).

Enzymatic Degradation:

TG2 Inhibition: ZED1227, a selective oral transglutaminase 2 inhibitor, attenuated gluten-induced mucosal damage (measured by villus height to crypt depth ratio) in a proof-of-concept trial ^[152]^A1b (1b). Transcriptomic analysis confirms it prevents gluten-induced intestinal inflammation ^[234]^A1b (1b).
Protease Therapy: Latiglutenase (IMGX003) has shown the ability to protect the mucosa and attenuate symptom severity during a gluten challenge ^[217]^A1b (1b), although earlier phase 2 studies showed no significant difference from placebo in reducing villous atrophy ^[221]^A1b (1b).

Immune Tolerance: TAK-101 nanoparticles, designed to induce gluten-specific tolerance, have been evaluated for safety and their ability to reduce gliadin-specific interferon- producing cells ^[215]^A1b (1b).

Step 4: Management of Refractory Celiac Disease (RCD)

Refractory celiac disease is defined by persistent malabsorption despite strict GFD adherence for 6-12 months.

RCD Type 1 (RCD1): Characterized by a normal phenotype of intraepithelial lymphocytes (IELs). Administer open-capsule budesonide to manage symptoms and inflammation ^[17]^C4 (4).
RCD Type 2 (RCD2): Characterized by clonal T-cell receptor gamma gene rearrangement and aberrant IELs. This form carries a high mortality risk. Consider JAK inhibitors; tofacitinib has demonstrated enduring clinical remission in a pilot study of therapy-refractory RCD2 ^[249]^C4 (4).

Drug and Modality Comparison Table

Option	Indication	Mechanism	Key Trial/Evidence	Outcome	Level
GFD	All CeD	Gluten avoidance	^[216]^A1b^[223]^A1b	Mucosal healing, symptom resolution	1b
Low FODMAP	Persistent symptoms	Reduce fermentable carbs	^[229]^A1b	Reduced GSRS-IBS scores	1b
ZED1227	Experimental	TG2 Inhibition	^[152]^A1b	Attenuated mucosal damage	1b
Larazotide	Persistent symptoms	Tight junction regulator	^[131]^A1b	Symptom relief (dose-dependent)	1b
Tofacitinib	RCD Type 2	JAK1/JAK3 Inhibition	^[249]^C4	Clinical remission in RCD2	4

Dosing Table

Drug	Starting dose	Target / max dose	Renal adjustment	Hepatic adjustment	Key monitoring
Budesonide	3-9 mg (open-capsule)	9 mg daily	No adjustment	Use caution	Stool gluten, symptoms
Tofacitinib	5 mg PO BID	5 mg PO BID	eGFR <30: reduce to 5 mg daily	B/C: avoid	CBC, lipids, LFTs
Larazotide	0.5 mg TID	2 mg TID	No adjustment	No adjustment	GSRS score
ZED1227	100 mg daily	100 mg daily	Not reported	Not reported	Villus height:crypt depth

What NOT to Do

Do NOT recommend cow's milk-based formula avoidance in at-risk infants to prevent celiac disease; RCT evidence shows this does not reduce the development of the disease ^[220]^A1b (1b).
Do NOT rely solely on symptom improvement to confirm GFD success; mucosal healing may lag behind symptom resolution, and some patients remain asymptomatic despite persistent villous atrophy ^[246]^B2b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Efficacy of Latiglutenase	Murray et al. ^[217]^A1b - Protects mucosa and attenuates symptoms in challenge	Murray et al. ^[221]^A1b - No difference vs placebo in reducing villous atrophy	Moderate	Conflicting results suggest efficacy may be limited to symptom management rather than full mucosal rescue.

Pearl: While a strict GFD is the only definitive treatment ^[12]^C4, persistent symptoms in mucosal remission should be managed by screening for non-gluten triggers like FODMAPs or HT rather than assuming GFD failure ^[222]^A1b^[229]^A1b^[135]^B2b.

Endoscopic and Procedural Management

▸Multiple biopsies (4-6 descending duodenum, 2-4 bulb) are essential to overcome the patchy nature of villous atrophy [31, 266].
▸Video Capsule Endoscopy (VCE) is the preferred first-line tool for screening the entire small bowel in non-responsive celiac disease [2, 148].
▸Double-Balloon Enteroscopy (DBE) is reserved for targeted biopsies of suspected EATL or lesions identified on VCE [260, 261].

! Warning: Avoid relying on a single biopsy specimen; the patchy distribution of celiac lesions significantly increases the risk of false-negative results [264].

Targeted mucosal sampling and advanced imaging modalities extend the diagnostic reach beyond standard upper endoscopy (UGIE) to address histologic patchiness and non-responsive disease. While the gold standard remains the histological assessment of the descending duodenum, the distribution of villous atrophy (VA) is often focal, necessitating strategic biopsy protocols to avoid false negatives ^[264]^B2b (2b).

Step 1: Optimized Mucosal Sampling

Obtain a minimum of 4 to 6 biopsy specimens from the descending duodenum and 2 to 4 from the duodenal bulb ^[31]^B3b (3b), ^[266]^B2b (2b), ^[271]^B2c (2c). The rationale for bulbar sampling is the high prevalence of patchy lesions; adding bulb biopsies increases the detection of abnormalities, although its impact on the overall rate of new celiac diagnoses in low-probability populations is minimal ^[263]^B3b (3b). In pediatric populations, adherence to taking $\ge$ 5 duodenal biopsies is widely practiced to mitigate sampling error ^[271]^B2c (2c).

Step 2: Advanced Endoscopic Imaging for VA Identification

When standard white-light endoscopy is inconclusive or when targeting biopsies in difficult cases, advanced imaging can enhance the visualization of the villous pattern:

Narrow-Band Imaging (NBI) and Chromo-zoom: NBI combined with water immersion techniques allows for a single-biopsy approach with a diagnostic sensitivity of 87.5% (95% CI 77.3-97.7%) ^[269]^B2b (2b). Chromo-zoom endoscopy provides high-resolution magnification to assess the degree of VA in patients with non-concordant serology or those who initiated a gluten-free diet (GFD) prematurely ^[154]^B3b (3b).
Optimal Band Imaging (OBI): This dye-free spectral processing enhances mucosal contrast, allowing clinicians to classify villous patterns as normal, partially atrophic, or markedly atrophic ^[255]^B2b (2b).
Confocal Endomicroscopy (CEM) and Endocytoscopy: CEM provides real-time, in vivo microscopy that can identify VA and crypt hypertrophy, potentially reducing the reliance on traditional histopathology ^[257]^B2b (2b), ^[33]^C4 (4). Endocytoscopy allows magnified live inspection (x450) to detect microstructural features of celiac sprue ^[178]^C4 (4), ^[32]^B2b (2b).

Step 3: Small-Bowel Evaluation in Non-Responsive Disease

Patients with non-responsive celiac disease (NRCD), defined by persistent symptoms despite a GFD, require evaluation of the distal small bowel to identify complications or dietary non-compliance.

Perform Video Capsule Endoscopy (VCE) as the first-line non-invasive tool ^[2]^A1c (1c). VCE can detect macroscopic features of VA in approximately 31% of patients with NRCD ^[173]^B3b (3b). Recent meta-analyses confirm VCE's utility in assisting diagnosis and monitoring the extent of mucosal changes across the entire small intestine ^[148]^A1a (1a), ^[259]^B2b (2b).

Escalate to Double-Balloon Enteroscopy (DBE) if VCE identifies suspicious lesions or if EATL is suspected ^[260]^B2b (2b). DBE is indicated for:

Biopsy of ulcerative jejunitis or suspected enteropathy-associated T-cell lymphoma (EATL) ^[260]^B2b (2b).
Investigation of pathology missed by VCE, as DBE can identify clinically significant lesions that VCE overlooks ^[261]^C4 (4).
Therapeutic interventions in the distal small bowel ^[181]^C4 (4).

Step 4: Monitoring and Longitudinal Assessment

Quantitative morphometry (measuring villous height and crypt length) provides more granular data on mucosal recovery than the semi-quantitative Marsh classification, particularly during the first 4 years of GFD ^[20]^B3b (3b). In refractory cases, immunohistochemical detection of neuroendocrine cell hyperplasia (e.g., chromogranin A) may serve as a marker for disease severity ^[258]^B3b (3b).

Caption: "Figure 1: Procedural escalation for non-responsive celiac disease (adapted from ^[2]^A1c, ^[173]^B3b, ^[260]^B2b)."

Modality Comparison for Small-Bowel Assessment

Modality	Indication	Capability	Key Limitation	Evidence Level
UGIE	Initial Diagnosis	Proximal biopsy (Bulb/Duodenum)	Misses distal patchiness	1c ^[262]^A1c
VCE	NRCD Screening	Full small-bowel visualization	No biopsy capability	1a ^[148]^A1a
DBE	High-risk NRCD	Full visualization + Biopsy	Invasive; higher risk	2b ^[260]^B2b
Push Enteroscopy	Pediatric/Proximal	Deeper proximal sampling	Limited reach compared to DBE	2b ^[264]^B2b

What NOT to Do

Do NOT rely on a single duodenal biopsy for diagnosis; the patchy nature of the disease requires multiple samples from both the bulb and the descending duodenum to avoid false negatives ^[264]^B2b (2b), ^[269]^B2b (2b).
Do NOT use VCE as a replacement for initial diagnosis in most patients, as histological confirmation via biopsy remains the gold standard ^[259]^B2b (2b).

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Necessity of Bulbar Biopsies	Standard Practice, routinely sample bulb to capture patchy VA ^[266]^B2b^[271]^B2c	Limited Utility, bulb biopsies increase yield but rarely change the final diagnosis in low-risk patients ^[263]^B3b	Moderate	Clinicians should prioritize bulb biopsies in high-suspicion/serology-positive cases but may omit them in routine screening.

Pearl: To minimize sampling error due to histologic patchiness, clinicians must obtain multiple biopsies from both the duodenal bulb and descending duodenum ^[31]^B3b^[266]^B2b; in non-responsive disease, VCE should precede DBE to guide targeted biopsies for EATL ^[173]^B3b^[260]^B2b.

Complications

▸T-cell lymphoma is more aggressive and more likely to be multifocal than small bowel adenocarcinoma in CD patients [277].
▸Essential amino acid malabsorption, particularly BCAAs, can persist despite treatment, leading to long-term metabolic and muscle deficits [290].
▸Enteroscopy remains the reference standard for detecting malignant lesions in complicated CD, as capsule endoscopy may yield false negatives [156, 261].

HY High Yield: Refractoriness to a gluten-free diet is a major red flag for T-cell lymphoma, occurring in 70% of cases [277].

Long-term sequelae of celiac disease (CD) range from localized mucosal damage to systemic malignancies, often correlating with the duration of undiagnosed disease or failure to adhere to a gluten-free diet ^[60]^D5^[113]^D5. Chronic inflammation and villous atrophy drive a spectrum of complications that necessitate lifelong surveillance, particularly for lymphoproliferative disorders ^[278]^B2b.

Small Bowel Malignancies

Small bowel adenocarcinoma (SBA) and T-cell lymphoma (TCL) are rare but aggressive malignancies associated with CD ^[277]^B3b. TCL is more frequently multifocal and presents at an advanced stage compared to SBA, which predominantly involves the jejunum ^[277]^B3b. Refractoriness to a gluten-free diet is a significant marker for TCL, identified in 70% of cases, whereas it was present in only one SBA case in a comparative series ^[277]^B3b. Survival outcomes are significantly worse for CD-associated TCL than for SBA (P < 0.01) ^[277]^B3b.

Sequelae

Chronic mucosal inflammation can lead to structural and inflammatory complications beyond simple malabsorption. Ulcerative enteritis (UE), or ulcerative jejunitis, is a rare complication that may present as intestinal obstruction, GI hemorrhage, or severe malabsorption ^[134]^C4. These ulcers can occur in the duodenum or exclusively distal to the angle of Treitz ^[134]^C4.

Occult gastrointestinal bleeding is a recognized contributor to iron deficiency in CD, suggesting a significant inflammatory hemorrhagic component that contradicts the traditional view of the disease as purely malabsorptive ^[281]^B3b. Additionally, patients with CD may develop comorbid , including both lymphocytic and collagenous subtypes ^[283]^B2b.

Systemic and Extra-intestinal Complications

Undiagnosed CD seropositivity is associated with increased long-term mortality and a higher incidence of cancer and other chronic diseases ^[278]^B2b. Beyond the small bowel, there is an association between CD and colorectal carcinoma (CRC), as gluten-induced immune-inflammatory effects may extend to the colon ^[125]^B2a.

Metabolic disruptions are common due to the malabsorption of essential amino acids (EAAs). Deficiencies in branched-chain amino acids (BCAAs) often persist even in treated patients, contributing to long-term muscle synthesis deficits ^[290]^D5. Tryptophan dysregulation is linked to mood disorders, while methionine disruptions impact antioxidant defense and homocysteine metabolism ^[290]^D5.

Surveillance and of Complications

Detection of premalignant or malignant lesions in complicated CD relies on a tiered endoscopic approach. Video capsule endoscopy (CE) is a noninvasive first-line tool to assess the small intestine ^[2]^A1c. However, CE can miss clinically significant pathology, necessitating the use of double-balloon enteroscopy (DBE) or other enteroscopy modalities for direct visualization and biopsy ^[156]^A1a^[261]^C4.

Complication	Frequency	Prevention	Management
T-cell Lymphoma	Rare	Strict gluten-free diet ^[277]^B3b	Chemotherapy/Surgery ^[277]^B3b
Small Bowel Adenocarcinoma	Rare	Strict gluten-free diet ^[277]^B3b	Surgical resection ^[277]^B3b
Ulcerative Enteritis	Rare	Gluten avoidance ^[134]^C4	Medical/Surgical based on obstruction ^[134]^C4
Colorectal Carcinoma	Low	screening ^[125]^B2a	Standard CRC protocols ^[125]^B2a
Microscopic Colitis	Variable	Gluten avoidance ^[283]^B2b	Anti-inflammatory therapy ^[283]^B2b

Pearl: CD-associated T-cell lymphoma carries a significantly worse prognosis than small bowel adenocarcinoma and is strongly associated with refractoriness to a gluten-free diet ^[277]^B3b.

Prognosis & Natural History

▸Strict GFD is the only proven treatment, but pVA predicts a higher risk of mortality and complications [94, 45].
▸Nonresponsive CD affects 7% to 30% of patients, usually due to gluten exposure, whereas Refractory CD (Type II) is a low-grade lymphoma with poor prognosis [204, 291].
▸Undiagnosed CD increases the risk of T-cell lymphoma, small bowel adenocarcinoma, and adverse pregnancy outcomes [277, 278, 292].

HY High Yield: Distinguish between NRCD and RCeD: NRCD is common and usually resolves with dietary correction, while RCeD is rare and potentially malignant (Type II) [291, 204].

Adherence to a strict, lifelong gluten-free diet (GFD) typically results in symptomatic remission and mucosal healing, though the trajectory varies significantly based on the timing of diagnosis and the presence of persistent villous atrophy (pVA) ^[45]^D5^[94]^B2b. In most patients, the GFD reverses malabsorption and reduces the risk of long-term complications, but a substantial subset fails to respond fully, either clinically or histologically ^[45]^D5.

Untreated and Undiagnosed Trajectories

Undiagnosed celiac disease (CD) carries a significant burden of morbidity and increased mortality ^[295]^B3b. Seropositivity in the absence of a clinical diagnosis is associated with an increased risk of cancer and other chronic diseases ^[278]^B2b. In women, "hidden" CD autoimmunity is linked to adverse reproductive characteristics and pregnancy outcomes ^[292]^B3b.

Patients with untreated CD face a heightened risk of malignancy, particularly lymphoproliferative disorders and cancers ^[104]^B2b. Small bowel adenocarcinoma (SBA) and T-cell lymphoma (TCL) are rare but aggressive; TCL generally presents with a worse prognosis than SBA, often involving multifocal disease and advanced stages ^[277]^B3b. Additionally, untreated CD is associated with an increased long-term risk of incident and recurrent acute pancreatitis ^[128]^B2b.

Treated Trajectory and Remission Dynamics

Mucosal recovery following GFD initiation is the primary predictor of long-term stability. However, pVA (Marsh $\ge$3a) despite a GFD is a critical marker of poor prognosis, as it predicts the development of further complications and increased mortality in adult patients ^[94]^B2b.

Patients may follow several distinct post-treatment paths:

Complete Remission: Resolution of symptoms and normalization of duodenal histology ^[194]^D5.
Nonresponsive Celiac Disease (NRCD): Persistent or recurrent symptoms despite $\ge$6 months of GFD ^[204]^B3b. This is relatively common, affecting 7% to 30% of patients, and is most frequently attributed to persistent gluten exposure ^[291]^D5^[204]^B3b.
Refractory Celiac Disease (RCeD): A rare condition where mucosal damage persists despite strict GFD. Type I RCeD is often a diagnosis of exclusion, while Type II RCeD represents a low-grade intraepithelial lymphoma with a significantly poorer prognosis ^[291]^D5.

Predictors of Outcome and Complications

Several clinical and histological markers shift a patient toward a higher-risk trajectory. Persistent villous atrophy is the most potent predictor of mortality and complication risk ^[94]^B2b. In pediatric populations, the time between diagnosis and treatment is critical; delayed diagnosis is associated with low bone mineral density (aBMD) ^[296]^B3b and anemia ^[118]^B2b.

Complication	Predictor/Association	Prognostic Impact
T-Cell Lymphoma	Refractoriness to GFD	Poor survival; often multifocal ^[277]^B3b
SBA	Chronic inflammation	Better survival than TCL ^[277]^B3b
Mortality	Persistent Villous Atrophy	Increased long-term risk ^[94]^B2b
Bone Loss	Delayed diagnosis (Pediatric)	Low aBMD Z-scores ^[296]^B3b
Liver Disease	Cryptogenic Cirrhosis	Favorable response to GFD ^[167]^B2b

Potential Celiac Disease (PCD) Progression

PCD, defined by CD-specific autoantibodies without villous atrophy, represents a pre-clinical stage of the disease ^[275]^D5. The natural history of PCD is heterogeneous; while some patients remain stable, others progress to full CD with villous atrophy ^[275]^D5^[293]^B2b. This transition is characterized by a shift from a blunted T helper type 1 response to full-scale mucosal inflammation ^[275]^D5.

Pearl: Persistent villous atrophy (Marsh $\ge$3a) despite a gluten-free diet is a primary predictor of increased mortality and the development of long-term complications ^[94]^B2b.

Special Populations & Prevention

▸Gluten introduction timing between 4 and 12 months does not reduce the risk of celiac disease in high-risk infants [82, 83].
▸T1D patients have a significantly higher prevalence of celiac disease, but standard serologic cut-offs may have low specificity in this population [108, 308].
▸Untreated celiac autoimmunity increases the risk of adverse pregnancy outcomes, making GFD adherence critical during gestation [292].

HY High Yield: Olmesartan-induced enteropathy is a critical differential diagnosis in elderly patients presenting with seronegative villous atrophy [95].

of celiac disease requires tailored strategies to account for the physiological and developmental differences across the lifespan and specific clinical states.

Pediatrics

Clinical presentation in children often deviates from the classic malabsorption syndrome. While failure to thrive and underweight remain common, there is an increasing prevalence of with normal or high BMI, which can lead to significant diagnostic delays ^[124]^B2a. In this population, the risk of developing the disease is strongly linked to HLA haplotype (DR3-DQ2 or DR4-DQ8) ^[168]^B2b^[305]^B2b.

Dietary introduction of gluten remains a point of clinical focus. Randomized trials indicate that introducing gluten at 6 months versus 12 months does not significantly alter the risk of developing celiac disease ^[83]^A1b. Similarly, providing 100 mg of immunologically active gluten daily to infants at high risk (HLA-positive with a first-degree relative) between 16 to 24 weeks of age did not reduce the frequency of biopsy-confirmed disease at 3 years ^[82]^A1b.

Pediatric management emphasizes the prevention of developmental delays and the mitigation of psychosocial stress. The lifelong requirement for a gluten-free diet (GFD) creates challenges for both the child and the caregiver; psychological interventions for parents have shown feasibility in improving the child's quality of life ^[232]^A1b. Furthermore, dietary counseling using a Gluten-Free Food Guide has been shown to increase dietary variety scores in newly diagnosed children ^[35]^A1b.

Pregnancy

Untreated celiac disease autoimmunity is associated with adverse reproductive outcomes. Women with "hidden" celiac autoimmunity (seropositive but not clinically diagnosed) exhibit higher rates of adverse pregnancy outcomes compared to seronegative controls ^[292]^B3b.

Strict adherence to a GFD is the primary intervention to optimize fetal and maternal health. Prospective data indicate that a GFD during pregnancy is safe and does not negatively impact obstetrical outcomes ^[129]^B2b. There are no specific dose modifications for the GFD during pregnancy, but nutritional monitoring is essential to prevent deficiencies that could affect fetal development.

Elderly

Presentation in the elderly is frequently atypical, often manifesting as non-specific symptoms or as part of a multisystem autoimmune cluster. Cognitive deficits and white matter changes have been observed in older adults with celiac disease compared to matched controls ^[303]^B3b.

Diagnostic thresholds in the elderly may be confounded by comorbidities. For example, severe sprue-like enteropathy can be induced by olmesartan, a common antihypertensive in this age group, which can mimic celiac disease histology but is seronegative ^[95]^B2b^[163]^B2b. Clinicians must differentiate between autoimmune celiac disease and drug-induced enteropathy to avoid lifelong unnecessary dietary restriction.

Immunocompromised and Comorbid States

Patients with Type 1 Diabetes (T1D) represent a high-risk group due to shared genetic loci, including RGS1 on chromosome 1q31 ^[108]^B2a^[309]^B3b. The prevalence of celiac disease is significantly higher in T1D patients, necessitating proactive screening. However, standard serologic thresholds may lack specificity in this group; for instance, IgA anti-tissue transglutaminase (tTG) at the upper limit of normal (30 CU) showed a sensitivity of 100% but a specificity of only 38% in asymptomatic T1D patients ^[308]^B2b.

Prevention and Screening

Primary prevention through dietary manipulation in infancy is not supported by current evidence ^[82]^A1b^[83]^A1b. Secondary prevention focuses on early detection in high-risk cohorts to prevent long-term complications, such as T-cell lymphoma or small bowel adenocarcinoma ^[277]^B3b.

Screening strategies include:

First-degree relatives: Recommended due to high genetic risk, although screening rates in practice remain low ^[295]^B3b.
Autoimmune comorbidities: Specifically T1D and autoimmune thyroid disease ^[108]^B2a^[314]^B3b.
Symptomatic overlap: Screening individuals with Irritable Bowel Syndrome (IBS) is recommended due to shared symptoms, although the diagnostic yield varies ^[90]^B2a.
Mass screening: In pediatric populations, mass screening using high-sensitivity tTG assays has been utilized to identify asymptomatic cases, though cost-effectiveness varies by region ^[301]^B2c^[306]^B2b^[117]^B2c.

Pearl: Early gluten introduction (4-12 months) does not prevent celiac disease in genetically predisposed infants ^[82]^A1b^[83]^A1b, shifting the clinical focus toward proactive screening of high-risk groups, particularly those with Type 1 Diabetes ^[108]^B2a.

References

[1]
Husby S, Murray JA, Katzka DA. “AGA Clinical Practice Update on Diagnosis and Monitoring of Celiac Disease-Changing Utility of Serology and Histologic Measures: Expert Review.” Gastroenterology (2018). PMID: 30578783 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[2]
Enns RA, Hookey L, Armstrong D et al.. “Clinical Practice Guidelines for the Use of Video Capsule Endoscopy.” Gastroenterology (2017). PMID: 28063287 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature, Endoscopic & Procedural Management, Complications
[3]
Leonard MM, Lebwohl B, Rubio-Tapia A et al.. “AGA Clinical Practice Update on the Evaluation and Management of Seronegative Enteropathies: Expert Review.” Gastroenterology (2020). PMID: 33010252 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature, Clinical Presentation
[4]
Lacy BE, Pimentel M, Brenner DM et al.. “ACG Clinical Guideline: Management of Irritable Bowel Syndrome.” The American journal of gastroenterology (2021). PMID: 33315591 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature
[5]
Lebwohl B, Ma C, Lagana SM et al.. “Standardizing Randomized Controlled Trials in Celiac Disease: An International Multidisciplinary Appropriateness Study.” Gastroenterology (2023). PMID: 37704112 ↗
L5RCTCited in: Definition, Classification & Nomenclature, Prognosis & Natural History, Special Populations & Prevention
[6]
Hindryckx P, Levesque BG, Holvoet T et al.. “Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials.” Gut (2016). PMID: 27799282 ↗
L2TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores)
[7]
Myléus A, Reilly NR, Green PHR. “Rate, Risk Factors, and Outcomes of Nonadherence in Pediatric Patients With Celiac Disease: A Systematic Review.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2019). PMID: 31173891 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature
[8]
Wu S, Yang Z, Liu S et al.. “Ultra-Processed Food Consumption and Long-Term Risk of Irritable Bowel Syndrome: A Large-Scale Prospective Cohort Study.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 38522476 ↗
L2COHORTCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores), Special Populations & Prevention
[9]
Abadie V, Han AS, Jabri B et al.. “New Insights on Genes, Gluten, and Immunopathogenesis of Celiac Disease.” Gastroenterology (2024). PMID: 38670280 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
[10]
Fasano A, Sapone A, Zevallos V et al.. “Nonceliac gluten sensitivity.” Gastroenterology (2015). PMID: 25583468 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Prognosis & Natural History
[11]
Mooney PD, Kurien M, Evans KE et al.. “Clinical and Immunologic Features of Ultra-Short Celiac Disease.” Gastroenterology (2016). PMID: 26836585 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification (GI Scores)
[12]
Risnes LF, Reims HM, Doyle RM et al.. “Gluten-Free Diet Induces Rapid Changes in Phenotype and Survival Properties of Gluten-Specific T Cells in Celiac Disease.” Gastroenterology (2024). PMID: 38552723 ↗
L4OTHERCited in: Definition, Classification & Nomenclature, Long-term & Definitive Medical Management
[13]
Ludvigsson JF, Agreus L, Ciacci C et al.. “Transition from childhood to adulthood in coeliac disease: the Prague consensus report.” Gut (2016). PMID: 27196596 ↗
L1OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[14]
Schmitz F, Kooy-Winkelaar Y, Wiekmeijer AS et al.. “The composition and differentiation potential of the duodenal intraepithelial innate lymphocyte compartment is altered in coeliac disease.” Gut (2015). PMID: 25966995 ↗
L3OTHERCited in: Definition, Classification & Nomenclature
[15]
Malamut G, Cellier C. “Is refractory celiac disease more severe in old Europe?” The American journal of gastroenterology (2011). PMID: 21540899 ↗
L5OTHERCited in: Definition, Classification & Nomenclature
[16]
Cassinotti A, Birindelli S, Clerici M et al.. “HLA and autoimmune digestive disease: a clinically oriented review for gastroenterologists.” The American journal of gastroenterology (2009). PMID: 19098870 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism
[17]
Mukewar SS, Sharma A, Rubio-Tapia A et al.. “Open-Capsule Budesonide for Refractory Celiac Disease.” The American journal of gastroenterology (2017). PMID: 28323276 ↗
L4OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Long-term & Definitive Medical Management, Special Populations & Prevention
[18]
Oxford EC, Nguyen DD, Sauk J et al.. “Impact of coexistent celiac disease on phenotype and natural history of inflammatory bowel diseases.” The American journal of gastroenterology (2013). PMID: 23419379 ↗
L3OTHERCited in: Definition, Classification & Nomenclature
[19]
Villanacci V, Bassotti G, Liserre B et al.. “Helicobacter pylori infection in patients with celiac disease.” The American journal of gastroenterology (2006). PMID: 16780559 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Clinical Presentation
[20]
Cummins AG, Alexander BG, Chung A et al.. “Morphometric evaluation of duodenal biopsies in celiac disease.” The American journal of gastroenterology (2010). PMID: 20736938 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification (GI Scores), Endoscopic & Procedural Management
[21]
Tignor AS, Wu BU, Whitlock TL et al.. “High prevalence of low-trauma fracture in chronic pancreatitis.” The American journal of gastroenterology (2010). PMID: 20736937 ↗
L3OTHERCited in: Definition, Classification & Nomenclature
[22]
Jensen ET, Eluri S, Lebwohl B et al.. “Increased Risk of Esophageal Eosinophilia and Eosinophilic Esophagitis in Patients With Active Celiac Disease on Biopsy.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2015). PMID: 25724709 ↗
L3OTHERCited in: Definition, Classification & Nomenclature
[23]
Bucci C, Zingone F, Russo I et al.. “Gliadin does not induce mucosal inflammation or basophil activation in patients with nonceliac gluten sensitivity.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 23639603 ↗
L4OTHERCited in: Definition, Classification & Nomenclature
[24]
Diosdado B, van Bakel H, Strengman E et al.. “Neutrophil recruitment and barrier impairment in celiac disease: a genomic study.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2007). PMID: 17336591 ↗
L4OTHERCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Long-term & Definitive Medical Management, Prognosis & Natural History
[25]
Kemppainen KM, Lynch KF, Liu E et al.. “Factors That Increase Risk of Celiac Disease Autoimmunity After a Gastrointestinal Infection in Early Life.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2016). PMID: 27840181 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[26]
Ermarth A, Bryce M, Woodward S et al.. “Identification of Pediatric Patients With Celiac Disease Based on Serology and a Classification and Regression Tree Analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2016). PMID: 27847281 ↗
L3OTHERCited in: Definition, Classification & Nomenclature
[27]
Taavela J, Kurppa K, Collin P et al.. “Degree of damage to the small bowel and serum antibody titers correlate with clinical presentation of patients with celiac disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2012). PMID: 23063678 ↗
L3OTHERCited in: Definition, Classification & Nomenclature
[28]
Lo A, Guelrud M, Essenfeld H et al.. “Classification of villous atrophy with enhanced magnification endoscopy in patients with celiac disease and tropical sprue.” Gastrointestinal endoscopy (2007). PMID: 17643717 ↗
L4OTHERCited in: Definition, Classification & Nomenclature
[29]
Sheiko MA, Feinstein JA, Capocelli KE et al.. “The concordance of endoscopic and histologic findings of 1000 pediatric EGDs.” Gastrointestinal endoscopy (2014). PMID: 25440693 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Endoscopic & Procedural Management
[30]
Gulati S, Emmanuel A, Ong M et al.. “Near-focus narrow-band imaging classification of villous atrophy in suspected celiac disease: development and international validation.” Gastrointestinal endoscopy (2021). PMID: 34228981 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification (GI Scores), Special Populations & Prevention
[31]
Pais WP, Duerksen DR, Pettigrew NM et al.. “How many duodenal biopsy specimens are required to make a diagnosis of celiac disease?” Gastrointestinal endoscopy (2008). PMID: 18308317 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores), Endoscopic & Procedural Management, Special Populations & Prevention
[32]
Pohl H, Rösch T, Tanczos BT et al.. “Endocytoscopy for the detection of microstructural features in adult patients with celiac sprue: a prospective, blinded endocytoscopy-conventional histology correlation study.” Gastrointestinal endoscopy (2009). PMID: 19560762 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification (GI Scores), Endoscopic & Procedural Management
[33]
Günther U, Daum S, Heller F et al.. “Diagnostic value of confocal endomicroscopy in celiac disease.” Endoscopy (2010). PMID: 20195989 ↗
L4OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Endoscopic & Procedural Management
[34]
Singh R, Nind G, Tucker G et al.. “Narrow-band imaging in the evaluation of villous morphology: a feasibility study assessing a simplified classification and observer agreement.” Endoscopy (2010). PMID: 21072704 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Endoscopic & Procedural Management
[35]
Jiang Z, Gidrewicz D, Chen M et al.. “A Gluten-Free Food Guide used in diet education to improve diet quality in children with newly diagnosed celiac disease: a pilot randomised control trial.” The British journal of nutrition (2025). PMID: 41190444 ↗
L1RCTCited in: Definition, Classification & Nomenclature, Long-term & Definitive Medical Management, Special Populations & Prevention
[36]
Pryor JC, Nieva C, Talley NJ et al.. “Microbial-derived peptidases are altered in celiac disease, non-celiac gluten sensitivity, and functional dyspepsia: a systematic review and re-analysis of the duodenal microbiome.” Gut microbes (2025). PMID: 40346812 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism
[37]
Ortiz G, Mora M, Toca MDC et al.. “[Pediatric guidelines for coeliac disease: Treatment and follow-up].” Archivos argentinos de pediatria (2024). PMID: 39699574 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature
[38]
Perananthan V, Mohammed MF, Beran A et al.. “Reassessing the Risk of Esophageal Cancer in Achalasia Post-Therapy: Findings From a Large United States Multi-Centre Retrospective Propensity-Matched Cohort Study.” Neurogastroenterology and motility (2025). PMID: 40887794 ↗
L3COHORTCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Endoscopic & Procedural Management
[39]
Bledsoe AC, Therrien A, Murray JA. “Drugs in Development and Clinical Trials for Celiac Disease.” Gastrointestinal endoscopy clinics of North America (2025). PMID: 41107014 ↗
L5TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature
[40]
Ciaccio EJ, Lee AR, Lebovits J et al.. “Psychological, Psychiatric, and Organic Brain Manifestations of Celiac Disease.” Digestive diseases (Basel, Switzerland) (2024). PMID: 38861947 ↗
L5SR_OBSCited in: Definition, Classification & Nomenclature
[41]
Moshiree B, Drossman D, Shaukat A. “AGA Clinical Practice Update on Evaluation and Management of Belching, Abdominal Bloating, and Distention: Expert Review.” Gastroenterology (2023). PMID: 37452811 ↗
L1GUIDELINECited in: Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[42]
Biesiekierski JR, Newnham ED, Irving PM et al.. “Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial.” The American journal of gastroenterology (2011). PMID: 21224837 ↗
L1RCTCited in: Pathophysiology & Mechanism, Acute Management, Long-term & Definitive Medical Management, Prognosis & Natural History
[43]
Aziz Q, Harris LA, Goodman BP et al.. “AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 40387691 ↗
L1GUIDELINECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors
[44]
Riches PL, McRorie E, Fraser WD et al.. “Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin.” The New England journal of medicine (2009). PMID: 19812402 ↗
L4CASE_REPORTCited in: Pathophysiology & Mechanism
[45]
Discepolo V, Kelly CP, Koning F et al.. “How Future Pharmacologic Therapies for Celiac Disease Will Complement the Gluten-Free Diet.” Gastroenterology (2024). PMID: 38604542 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Prognosis & Natural History
[46]
Schuppan D, Junker Y, Barisani D. “Celiac disease: from pathogenesis to novel therapies.” Gastroenterology (2009). PMID: 19766641 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification (GI Scores), Prognosis & Natural History
[47]
Galipeau HJ, Hinterleitner R, Leonard MM et al.. “Non-Host Factors Influencing Onset and Severity of Celiac Disease.” Gastroenterology (2024). PMID: 38286392 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification (GI Scores)
[48]
Adams DW, Moleski S, Jossen J et al.. “Clinical Presentation and Spectrum of Gluten Symptomatology in Celiac Disease.” Gastroenterology (2024). PMID: 38636679 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation
[49]
du Pré MF, Kleppa L, Dewan AE et al.. “Peyer's Patch B Cells Sample Transglutaminase-Gluten Complexes and Drive Celiac Disease Autoimmunity.” Gastroenterology (2025). PMID: 40602545 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[50]
Verdu EF, Schuppan D. “Co-factors, Microbes, and Immunogenetics in Celiac Disease to Guide Novel Approaches for Diagnosis and Treatment.” Gastroenterology (2021). PMID: 34416277 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Prognosis & Natural History
[51]
Constante M, Libertucci J, Galipeau HJ et al.. “Biogeographic Variation and Functional Pathways of the Gut Microbiota in Celiac Disease.” Gastroenterology (2022). PMID: 35810781 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[52]
Dydensborg Sander S, Nybo Andersen AM, Murray JA et al.. “Association Between Antibiotics in the First Year of Life and Celiac Disease.” Gastroenterology (2019). PMID: 30836095 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification (GI Scores), Special Populations & Prevention
[53]
Damianos JA, Bledsoe A, Camilleri M et al.. “Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration.” Gut (2026). PMID: 40579122 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term & Definitive Medical Management, Prognosis & Natural History
[54]
Olazagoitia-Garmendia A, Zhang L, Mera P et al.. “Gluten-induced RNA methylation changes regulate intestinal inflammation via allele-specific XPO1 translation in epithelial cells.” Gut (2021). PMID: 33526437 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[55]
Uhde M, Ajamian M, Caio G et al.. “Intestinal cell damage and systemic immune activation in individuals reporting sensitivity to wheat in the absence of coeliac disease.” Gut (2016). PMID: 27459152 ↗
L4OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[56]
Barone MV, Gimigliano A, Castoria G et al.. “Growth factor-like activity of gliadin, an alimentary protein: implications for coeliac disease.” Gut (2006). PMID: 16891357 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[57]
Silvester JA, Therrien A, Kelly CP. “Celiac Disease: Fallacies and Facts.” The American journal of gastroenterology (2021). PMID: 33767109 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[58]
Aziz I. “The Global Phenomenon of Self-Reported Wheat Sensitivity.” The American journal of gastroenterology (2018). PMID: 29915404 ↗
L5OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[59]
Wungjiranirun M, Kelly CP, Leffler DA. “Current Status of Celiac Disease Drug Development.” The American journal of gastroenterology (2016). PMID: 27021196 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[60]
Pinier M, Fuhrmann G, Verdu EF et al.. “Prevention measures and exploratory pharmacological treatments of celiac disease.” The American journal of gastroenterology (2010). PMID: 20877349 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Complications
[61]
Boettcher E, Crowe SE. “Dietary proteins and functional gastrointestinal disorders.” The American journal of gastroenterology (2013). PMID: 23567359 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[62]
Wolters VM, Wijmenga C. “Genetic background of celiac disease and its clinical implications.” The American journal of gastroenterology (2008). PMID: 18184122 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[63]
Leontiadis GI, Longstreth GF. “Evolutionary Medicine Perspectives: Helicobacter pylori, Lactose Intolerance, and 3 Hypotheses for Functional and Inflammatory Gastrointestinal and Hepatobiliary Disorders.” The American journal of gastroenterology (2022). PMID: 35169106 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[64]
Lebwohl B, Murray JA, Verdú EF et al.. “Gluten Introduction, Breastfeeding, and Celiac Disease: Back to the Drawing Board.” The American journal of gastroenterology (2015). PMID: 26259710 ↗
L5OTHERCited in: Pathophysiology & Mechanism
[65]
Costigan CM, Warren FJ, Duncan AP et al.. “One Year of Gluten-Free Diet Impacts Gut Function and Microbiome in Celiac Disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 39662692 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[66]
Khan A, Suarez MG, Murray JA. “Nonceliac Gluten and Wheat Sensitivity.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2019). PMID: 30978535 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[67]
Lacy BE. “The Science, Evidence, and Practice of Dietary Interventions in Irritable Bowel Syndrome.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2015). PMID: 25769411 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Prognosis & Natural History
[68]
Adams DW, Patel D, Evers L et al.. “Measurements of Duodenal Mucosal Integrity Are Altered in Celiac Disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2019). PMID: 31351133 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[69]
Carroccio A, Giannone G, Mansueto P et al.. “Duodenal and Rectal Mucosa Inflammation in Patients With Non-celiac Wheat Sensitivity.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2018). PMID: 30138736 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[70]
Perfetti V, Baldanti F, Lenti MV et al.. “Detection of Active Epstein-Barr Virus Infection in Duodenal Mucosa of Patients With Refractory Celiac Disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2016). PMID: 27033429 ↗
L3OTHERCited in: Pathophysiology & Mechanism
[71]
Chang D, O'Shea D, Therrien A et al.. “Review article: Becoming and being coeliac-special considerations for childhood, adolescence and beyond.” Alimentary pharmacology & therapeutics (2022). PMID: 35815825 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Prevention
[72]
Rashtak S, Murray JA. “Review article: coeliac disease, new approaches to therapy.” Alimentary pharmacology & therapeutics (2012). PMID: 22324389 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[73]
Conell-Price J. “Neurologic Manifestations of Hepatic and Gastrointestinal Disease.” Continuum (Minneapolis, Minn.) (2026). PMID: 41631918 ↗
L5CASE_REPORTCited in: Pathophysiology & Mechanism
[74]
Diers A, Rudloff S, Hausmann H et al.. “Cyanidin and delphinidin inhibit transglutaminase 2 and mitigate inflammatory effects of IFN-γ and TNF-α by molecular interaction.” Food & function (2026). PMID: 42171256 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[75]
Montefusco A, Bellone ML, Romanelli AM et al.. “Proteomic Analysis Highlights Peculiar Protein and Phosphoprotein Profiles in Dermal Fibroblasts from Celiac Disease Patients.” International journal of molecular sciences (2026). PMID: 42123523 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[76]
Moleriu LC, Lupusoru R, Marin RC et al.. “Food as Friend or Foe: A Decadal Narrative Review of Dietary Patterns as Determinants of Gastrointestinal Pathophysiology and Clinical Outcomes (2015-2025).” International journal of molecular sciences (2026). PMID: 41898696 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[77]
Yang J, Mramba LK, Hård Af Segerstad EM et al.. “Longitudinal micronutrient exposure reveals country-specific associations with risk of celiac disease in genetically susceptible children: the prospective TEDDY cohort.” The American journal of clinical nutrition (2026). PMID: 41850488 ↗
L2OTHERCited in: Pathophysiology & Mechanism
[78]
Salamon D, Krawczyk A, Zapała B et al.. “Gut bacterial and fungal signatures in relation to human leukocyte antigen-DQ2/DQ8 in children with celiac disease and siblings.” World journal of gastroenterology (2026). PMID: 41809456 ↗
L3OTHERCited in: Pathophysiology & Mechanism
[79]
Tarancon-Diez L, Perez-Cabeza G, Sanchez-Mingo P et al.. “The hidden link between iron deficiency and celiac disease: a clinical perspective.” Frontiers in immunology (2026). PMID: 41798956 ↗
L3OTHERCited in: Pathophysiology & Mechanism
[80]
Officer A, Watson CT, Engelbrecht E et al.. “Immunoglobulin gene polymorphisms shape the naïve B-cell receptor repertoire; relevance to celiac disease.” Genes and immunity (2026). PMID: 41748905 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[81]
Rubio-Tapia A, Hill ID, Kelly CP et al.. “ACG clinical guidelines: diagnosis and management of celiac disease.” The American journal of gastroenterology (2013). PMID: 23609613 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[82]
Vriezinga SL, Auricchio R, Bravi E et al.. “Randomized feeding intervention in infants at high risk for celiac disease.” The New England journal of medicine (2014). PMID: 25271603 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Acute Management, Long-term & Definitive Medical Management, Special Populations & Prevention
[83]
Lionetti E, Castellaneta S, Francavilla R et al.. “Introduction of gluten, HLA status, and the risk of celiac disease in children.” The New England journal of medicine (2014). PMID: 25271602 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Long-term & Definitive Medical Management, Special Populations & Prevention
[84]
Shiha MG, Nandi N, Raju SA et al.. “Accuracy of the No-Biopsy Approach for the Diagnosis of Celiac Disease in Adults: A Systematic Review and Meta-Analysis.” Gastroenterology (2024). PMID: 38176661 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[85]
Mahadev S, Laszkowska M, Sundström J et al.. “Prevalence of Celiac Disease in Patients With Iron Deficiency Anemia-A Systematic Review With Meta-analysis.” Gastroenterology (2018). PMID: 29689265 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
[86]
Pinto-Sanchez MI, Seiler CL, Santesso N et al.. “Association Between Inflammatory Bowel Diseases and Celiac Disease: A Systematic Review and Meta-Analysis.” Gastroenterology (2020). PMID: 32416141 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[87]
Romanos J, Rosén A, Kumar V et al.. “Improving coeliac disease risk prediction by testing non-HLA variants additional to HLA variants.” Gut (2013). PMID: 23704318 ↗
L3TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores)
[88]
King JA, Jeong J, Underwood FE et al.. “Incidence of Celiac Disease Is Increasing Over Time: A Systematic Review and Meta-analysis.” The American journal of gastroenterology (2020). PMID: 32022718 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[89]
Yoosuf S, Singh P, Khaitan A et al.. “Prevalence of Celiac Disease in Patients With Liver Diseases: A Systematic Review and Meta-Analyses.” The American journal of gastroenterology (2022). PMID: 36599134 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[90]
Irvine AJ, Chey WD, Ford AC. “Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis.” The American journal of gastroenterology (2016). PMID: 27753436 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Prevention
[91]
Karimzadhagh S, Abbaspour E, Ghodous S et al.. “Global Prevalence and Clinical Manifestations of Celiac Disease Among First-Degree Relatives: A Systematic Review and Meta-Analysis.” The American journal of gastroenterology (2024). PMID: 39584667 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[92]
Shiha MG, Schiepatti A, Manza F et al.. “Global Prevalence of Celiac Disease in Patients With Rome III and Rome IV Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis.” The American journal of gastroenterology (2025). PMID: 40493044 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[93]
Kurien M, Evans KE, Hopper AD et al.. “Duodenal bulb biopsies for diagnosing adult celiac disease: is there an optimal biopsy site?” Gastrointestinal endoscopy (2012). PMID: 22624810 ↗
L2RCTCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Prevention
[94]
Schiepatti A, Maimaris S, Raju SA et al.. “Persistent villous atrophy predicts development of complications and mortality in adult patients with coeliac disease: a multicentre longitudinal cohort study and development of a score to identify high-risk patients.” Gut (2023). PMID: 37364982 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores), Prognosis & Natural History
[95]
Basson M, Mezzarobba M, Weill A et al.. “Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study.” Gut (2015). PMID: 26250345 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification (GI Scores), Special Populations & Prevention
[96]
Röckert Tjernberg A, Mårild K, Söderling J et al.. “Celiac Disease and Serious Infections: A Nationwide Cohort Study From 2002 to 2017.” The American journal of gastroenterology (2022). PMID: 35973180 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors
[97]
Mårild K, Söderling J, Lebwohl B et al.. “Association of Celiac Disease and Inflammatory Bowel Disease: A Nationwide Register-Based Cohort Study.” The American journal of gastroenterology (2022). PMID: 35613563 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors
[98]
Singh P, Arora A, Strand TA et al.. “Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2018). PMID: 29551598 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Prevention
[99]
Celdir MG, Jansson-Knodell CL, Hujoel IA et al.. “Latitude and Celiac Disease Prevalence: A Meta-Analysis and Meta-Regression.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2020). PMID: 33007509 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Prevention
[100]
Jansson-Knodell CL, Hujoel IA, West CP et al.. “Sex Difference in Celiac Disease in Undiagnosed Populations: A Systematic Review and Meta-analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2018). PMID: 30448593 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Prevention
[101]
Sainsbury A, Sanders DS, Ford AC. “Prevalence of irritable bowel syndrome-type symptoms in patients with celiac disease: a meta-analysis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2012). PMID: 23246645 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[102]
Kurien M, Evans KE, Aziz I et al.. “Capsule endoscopy in adult celiac disease: a potential role in equivocal cases of celiac disease?” Gastrointestinal endoscopy (2012). PMID: 23200728 ↗
L2TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Prevention
[103]
Barada K, Habib RH, Malli A et al.. “Prediction of celiac disease at endoscopy.” Endoscopy (2014). PMID: 24477366 ↗
L2TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Prevention
[104]
Lebwohl B, Green PHR, Emilsson L et al.. “Cancer Risk in 47,241 Individuals With Celiac Disease: A Nationwide Cohort Study.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2021). PMID: 34033925 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History
[105]
Raju SA, Greenaway EA, Schiepatti A et al.. “New entity of adult ultra-short coeliac disease: the first international cohort and case-control study.” Gut (2024). PMID: 38499339 ↗
L3CASE_CONTROLCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[106]
Elfström P, Sundström J, Ludvigsson JF. “Systematic review with meta-analysis: associations between coeliac disease and type 1 diabetes.” Alimentary pharmacology & therapeutics (2014). PMID: 25270960 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[107]
Canestaro WJ, Edwards TC, Patrick DL. “Systematic review: patient-reported outcome measures in coeliac disease for regulatory submissions.” Alimentary pharmacology & therapeutics (2016). PMID: 27349458 ↗
L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores), Prognosis & Natural History
[108]
Karimzadhagh S, Abbaspour E, Shahriarinamin M et al.. “Meta-Analysis: Global Prevalence of Coeliac Disease in Type 1 Diabetes.” Alimentary pharmacology & therapeutics (2024). PMID: 39497278 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Special Populations & Prevention
[109]
Kang JY, Kang AH, Green A et al.. “Systematic review: worldwide variation in the frequency of coeliac disease and changes over time.” Alimentary pharmacology & therapeutics (2013). PMID: 23782240 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[110]
Lebwohl B, Rubio-Tapia A. “Epidemiology, Presentation, and Diagnosis of Celiac Disease.” Gastroenterology (2020). PMID: 32950520 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[111]
Zingone F, Bai JC, Cellier C et al.. “Celiac Disease-Related Conditions: Who to Test?” Gastroenterology (2024). PMID: 38460606 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
[112]
Volta U, Rostami K, Auricchio R et al.. “Diagnosis of Seronegative and Ultrashort Celiac Disease.” Gastroenterology (2024). PMID: 38286391 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[113]
Kelly CP, Bai JC, Liu E et al.. “Advances in diagnosis and management of celiac disease.” Gastroenterology (2015). PMID: 25662623 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Complications, Prognosis & Natural History
[114]
Gatti S, Rubio-Tapia A, Makharia G et al.. “Patient and Community Health Global Burden in a World With More Celiac Disease.” Gastroenterology (2024). PMID: 38309629 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Special Populations & Prevention
[115]
Olivares M, Neef A, Castillejo G et al.. “The HLA-DQ2 genotype selects for early intestinal microbiota composition in infants at high risk of developing coeliac disease.” Gut (2014). PMID: 24939571 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[116]
Green PH. “Where are all those patients with Celiac disease?” The American journal of gastroenterology (2007). PMID: 17593160 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History
[117]
Mäkinen J, Heikkilä P, Pajula J et al.. “Screening for Celiac Disease in Childhood: Cost-Effectiveness of Multiple Genetic and Serological Testing Approaches.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2025). PMID: 41407089 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Prevention
[118]
Repo M, Rajalahti T, Hiltunen P et al.. “Diagnostic findings and long-term prognosis in children with anemia undergoing GI endoscopies.” Gastrointestinal endoscopy (2020). PMID: 31917169 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Prognosis & Natural History, Special Populations & Prevention
[119]
Lebwohl B, Tennyson CA, Holub JL et al.. “Sex and racial disparities in duodenal biopsy to evaluate for celiac disease.” Gastrointestinal endoscopy (2012). PMID: 22732871 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Prevention
[120]
Latorre M, Lagana SM, Freedberg DE et al.. “Endoscopic biopsy technique in the diagnosis of celiac disease: one bite or two?” Gastrointestinal endoscopy (2015). PMID: 25638509 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores), Special Populations & Prevention
[121]
Lebwohl B, Kapel RC, Neugut AI et al.. “Adherence to biopsy guidelines increases celiac disease diagnosis.” Gastrointestinal endoscopy (2011). PMID: 21601201 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[122]
Goyal O, Goyal MK, Gupta A et al.. “Prevalence and predictors of nonceliac wheat sensitivity in refractory irritable bowel syndrome and functional dyspepsia: results from a randomized double-blind placebo-controlled study.” European journal of gastroenterology & hepatology (2025). PMID: 41025571 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Long-term & Definitive Medical Management, Prognosis & Natural History
[123]
Desalegn D, Fischer S, Bedada Y et al.. “Autoimmunity to mental health: Risk of depression in type 1 diabetes and celiac disease patients - A systematic review, meta-analysis, and bias assessment.” Journal of autoimmunity (2026). PMID: 41538974 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[124]
Maleki F, Hosseinpour M, Pashaei MR et al.. “Body mass index in children with newly diagnosed celiac disease: A systematic review and meta-analysis.” European journal of pediatrics (2025). PMID: 41398527 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Special Populations & Prevention
[125]
Khayyat YM. “Colonic neoplasia and celiac disease: A systematic review.” World journal of gastroenterology (2025). PMID: 41025080 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Complications, Prognosis & Natural History
[126]
Zingone F, Canova C, Forss A et al.. “Prevalence of Celiac Disease in Patients With Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis.” Liver international : official journal of the International Association for the Study of the Liver (2025). PMID: 40827883 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[127]
Thakkar K, Chen L, Tatevian N et al.. “Diagnostic yield of oesophagogastroduodenoscopy in children with abdominal pain.” Alimentary pharmacology & therapeutics (2009). PMID: 19573168 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Prevention
[128]
Yao J, Sun J, Ebrahimi F et al.. “Long-term risk of acute pancreatitis in patients with celiac disease: A nationwide population-based cohort study.” Journal of internal medicine (2026). PMID: 41685430 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Prognosis & Natural History, Special Populations & Prevention
[129]
Srajer A, Harris M, Santos J et al.. “Obstetrical outcomes in pregnant patients following a gluten-free diet: A prospective cohort study.” International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2026). PMID: 41614439 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores), Prognosis & Natural History, Special Populations & Prevention
[130]
Mpakosi A, Cholevas V, Tsantes AG et al.. “Mass Screening Strategies for Celiac Disease in Apparently Healthy Children and Adolescents: A Systematic Review.” Medicina (Kaunas, Lithuania) (2026). PMID: 41752646 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Prevention
[131]
Leffler DA, Kelly CP, Green PH et al.. “Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.” Gastroenterology (2015). PMID: 25683116 ↗
L1RCTCited in: Clinical Presentation, Acute Management, Long-term & Definitive Medical Management
[132]
Carroccio A, Mansueto P, Iacono G et al.. “Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity.” The American journal of gastroenterology (2012). PMID: 22825366 ↗
L3RCTCited in: Clinical Presentation, Severity, Staging & Risk Stratification (GI Scores)
[133]
Camilleri M, Vijayvargiya P. “The Role of Bile Acids in Chronic Diarrhea.” The American journal of gastroenterology (2020). PMID: 32558690 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[134]
Chornenkyy Y, Peric M, Flores DM et al.. “Ulcerative Jejunitis in Celiac Disease: A 30-Year US Experience.” The American journal of gastroenterology (2024). PMID: 39471499 ↗
L4OTHERCited in: Clinical Presentation, Complications, Special Populations & Prevention
[135]
Therrien A, Akula S, Galeas-Pena M et al.. “Hereditary Alpha-Tryptasemia Is Associated With Ongoing Symptoms in Individuals With Celiac Disease Despite Following a Gluten-free Diet.” The American journal of gastroenterology (2025). PMID: 40367491 ↗
L2OTHERCited in: Clinical Presentation, Long-term & Definitive Medical Management
[136]
Hashash JG, Squire J, Francis FF et al.. “An Expert Opinion/Approach: Clinical Presentations, Diagnostic Considerations, and Therapeutic Options for Gastrointestinal Manifestations of Common Variable Immune Deficiency.” The American journal of gastroenterology (2022). PMID: 36148549 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[137]
Vande Voort JL, Murray JA, Lahr BD et al.. “Lymphocytic duodenosis and the spectrum of celiac disease.” The American journal of gastroenterology (2009). PMID: 19098862 ↗
L3OTHERCited in: Clinical Presentation
[138]
West J, Fleming KM, Tata LJ et al.. “Incidence and prevalence of celiac disease and dermatitis herpetiformis in the UK over two decades: population-based study.” The American journal of gastroenterology (2014). PMID: 24667576 ↗
L2OTHERCited in: Clinical Presentation
[139]
Srinivas M, Basumani P, Podmore G et al.. “Utility of testing patients, on presentation, for serologic features of celiac disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 24262940 ↗
L3OTHERCited in: Clinical Presentation
[140]
Dominguez Castro P, Harkin G, Hussey M et al.. “Changes in Presentation of Celiac Disease in Ireland From the 1960s to 2015.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2016). PMID: 28043932 ↗
L3OTHERCited in: Clinical Presentation
[141]
Nachman F, Vázquez H, González A et al.. “Gastroesophageal reflux symptoms in patients with celiac disease and the effects of a gluten-free diet.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2010). PMID: 20601132 ↗
L2OTHERCited in: Clinical Presentation
[142]
Abu Daya H, Lebwohl B, Lewis SK et al.. “Celiac disease patients presenting with anemia have more severe disease than those presenting with diarrhea.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 23756221 ↗
L3OTHERCited in: Clinical Presentation
[143]
Halfdanarson TR, Rubio-Tapia A, Ristow KM et al.. “Patients with celiac disease and B-cell lymphoma have a better prognosis than those with T-cell lymphoma.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2010). PMID: 20851210 ↗
L3OTHERCited in: Clinical Presentation
[144]
Caprai S, Vajro P, Ventura A et al.. “Autoimmune liver disease associated with celiac disease in childhood: a multicenter study.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2008). PMID: 18258488 ↗
L3OTHERCited in: Clinical Presentation, Long-term & Definitive Medical Management
[145]
Miceli E, Lenti MV, Padula D et al.. “Common features of patients with autoimmune atrophic gastritis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2012). PMID: 22387252 ↗
L4OTHERCited in: Clinical Presentation
[146]
Linssen JDG, Schafrat PJM, de Back TR et al.. “Predisposing conditions in patients with small intestinal adenocarcinomas in the Netherlands: A 20-year nationwide cohort study.” International journal of cancer (2025). PMID: 39907526 ↗
L2COHORTCited in: Clinical Presentation, Prognosis & Natural History
[147]
Stirrat T, Wilkey M, Kim S et al.. “Collagenous sprue across five decades (1970-2025): a systematic review.” Scandinavian journal of gastroenterology (2026). PMID: 41854086 ↗
L2SR_OBSCited in: Clinical Presentation, Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Prevention
[148]
Shapiro M, Niv Y. “Diagnostic Yield of Video Capsule Endoscopy (VCE) in Celiac Disease (CD): A Systematic Review and Meta-analysis.” Journal of clinical gastroenterology (2025). PMID: 40434820 ↗
L1SR_OBSCited in: Clinical Presentation, Endoscopic & Procedural Management
[149]
Nesterowicz M, Anikiej K, Borysewicz-Sańczyk H et al.. “Case Report: Autoimmune polyglandular syndrome type 4 involving diabetes mellitus type 1, autoimmune hepatitis, immune thrombocytopenia, and celiac disease.” Frontiers in endocrinology (2025). PMID: 41169469 ↗
L4CASE_REPORTCited in: Clinical Presentation
[150]
Bossi G, Gorone MSP, Lungarotti L et al.. “A child with Chronic Nonbacterial Osteomyelitis and celiac disease: accidental association or two different aspects of the same condition?” Italian journal of pediatrics (2025). PMID: 39885545 ↗
L4CASE_REPORTCited in: Clinical Presentation
[151]
Snipaitiene A, Radzeviciute L, Aleknaviciene K et al.. “Case report: Looking for relationship between type 1 diabetes and chronic recurrent osteomyelitis: short literature review and case presentation.” Frontiers in endocrinology (2025). PMID: 39845887 ↗
L4CASE_REPORTCited in: Clinical Presentation
[152]
Schuppan D, Mäki M, Lundin KEA et al.. “A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease.” The New England journal of medicine (2021). PMID: 34192430 ↗
L1RCTCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores), Acute Management, Long-term & Definitive Medical Management
[153]
Pinto-Sánchez MI, Causada-Calo N, Bercik P et al.. “Safety of Adding Oats to a Gluten-Free Diet for Patients With Celiac Disease: Systematic Review and Meta-analysis of Clinical and Observational Studies.” Gastroenterology (2017). PMID: 28431885 ↗
L1SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Prognosis & Natural History, Special Populations & Prevention
[154]
Iovino P, Pascariello A, Russo I et al.. “Difficult diagnosis of celiac disease: diagnostic accuracy and utility of chromo-zoom endoscopy.” Gastrointestinal endoscopy (2012). PMID: 23200727 ↗
L3TRIAL_NONRANDOMCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Endoscopic & Procedural Management
[155]
Maimaris S, Baschiera G, Sammartino C et al.. “Endoscopic techniques for the identification of duodenal villous atrophy in celiac disease: a systematic review and meta-analysis of diagnostic accuracy.” Gastrointestinal endoscopy (2025). PMID: 41456747 ↗
L1SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Endoscopic & Procedural Management
[156]
Elli L, Casazza G, Locatelli M et al.. “Use of enteroscopy for the detection of malignant and premalignant lesions of the small bowel in complicated celiac disease: a meta-analysis.” Gastrointestinal endoscopy (2017). PMID: 28433612 ↗
L1SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Complications
[157]
Tursi A, Brandimarte G, Giorgetti GM et al.. “Endoscopic and histological findings in the duodenum of adults with celiac disease before and after changing to a gluten-free diet: a 2-year prospective study.” Endoscopy (2006). PMID: 16810593 ↗
L2TRIAL_NONRANDOMCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Prevention
[158]
Hopper AD, Cross SS, Sanders DS. “Patchy villous atrophy in adult patients with suspected gluten-sensitive enteropathy: is a multiple duodenal biopsy strategy appropriate?” Endoscopy (2008). PMID: 18058655 ↗
L2TRIAL_NONRANDOMCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Severity, Staging & Risk Stratification (GI Scores), Special Populations & Prevention
[159]
Mårild K, Söderling J, Lebwohl B et al.. “Association Between Celiac Disease and Irritable Bowel Syndrome: A Nationwide Cohort Study.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 38367742 ↗
L2COHORTCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Prevention
[160]
Moscatelli OG, Russell AK, Henneken LM et al.. “Blood-Based T-Cell Diagnosis of Celiac Disease.” Gastroenterology (2025). PMID: 40499737 ↗
L3OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Prevention
[161]
Robert ME, Ciacci C, Lebwohl B. “Opportunities for Improving Biopsy and Non-Biopsy-Based Diagnosis of Celiac Disease.” Gastroenterology (2024). PMID: 38302007 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[162]
Johansen A, Sandve GKF, Ibsen JH et al.. “Biopsy Proteome Scoring to Determine Mucosal Remodeling in Celiac Disease.” Gastroenterology (2024). PMID: 38467384 ↗
L4OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Long-term & Definitive Medical Management
[163]
Aziz I, Peerally MF, Barnes JH et al.. “The clinical and phenotypical assessment of seronegative villous atrophy; a prospective UK centre experience evaluating 200 adult cases over a 15-year period (2000-2015).” Gut (2016). PMID: 27605538 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Prevention
[164]
Rubio-Tapia A, Hill ID, Semrad C et al.. “American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease.” The American journal of gastroenterology (2022). PMID: 36602836 ↗
L1OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[165]
Verdu EF, Armstrong D, Murray JA. “Between celiac disease and irritable bowel syndrome: the "no man's land" of gluten sensitivity.” The American journal of gastroenterology (2009). PMID: 19455131 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Prognosis & Natural History
[166]
Cappell K, Taylor A, Johnson BH et al.. “Healthcare Resource Utilization and Costs in Celiac Disease: A US Claims Analysis.” The American journal of gastroenterology (2020). PMID: 33156101 ↗
L3OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[167]
Pachisia AV, Agarwal A, Mehta S et al.. “Celiac Disease Is Common in Adults With Cryptogenic Cirrhosis and Responds Favorably to Gluten-Free Diet.” The American journal of gastroenterology (2024). PMID: 40315384 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Prognosis & Natural History
[168]
Liu E, Lee HS, Aronsson CA et al.. “Risk of pediatric celiac disease according to HLA haplotype and country.” The New England journal of medicine (2014). PMID: 24988556 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Prevention
[169]
Jansson-Knodell CL, Rubio-Tapia A. “Gluten-related Disorders From Bench to Bedside.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2023). PMID: 37879521 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[170]
Ferretti F, Branchi F, Orlando S et al.. “Effectiveness of Capsule Endoscopy and Double-Balloon Enteroscopy in Suspected Complicated Celiac Disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2020). PMID: 33189853 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Prognosis & Natural History, Special Populations & Prevention
[171]
Syage JA, Mäki M, Leffler DA et al.. “A Composite Morphometric Duodenal Biopsy Mucosal Scale for Celiac Disease Encompassing Both Morphology and Inflammation.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2023). PMID: 37952751 ↗
L4OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[172]
Bozorg SR, Söderling J, Everhov ÅH et al.. “Work Loss in Patients With Celiac Disease: A Population-based Longitudinal Study.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2021). PMID: 34509642 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[173]
Atlas DS, Rubio-Tapia A, Van Dyke CT et al.. “Capsule endoscopy in nonresponsive celiac disease.” Gastrointestinal endoscopy (2011). PMID: 21835400 ↗
L3OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Endoscopic & Procedural Management, Prognosis & Natural History
[174]
Chetcuti Zammit S, Schiepatti A, Aziz I et al.. “Use of small-bowel capsule endoscopy in cases of equivocal celiac disease.” Gastrointestinal endoscopy (2020). PMID: 31923404 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Prognosis & Natural History
[175]
Daum S, Wahnschaffe U, Glasenapp R et al.. “Capsule endoscopy in refractory celiac disease.” Endoscopy (2007). PMID: 17516353 ↗
L4OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Prevention
[176]
Delvaux M, Gay G. “International Conference on Capsule and Double-Balloon Endoscopy (ICCD). Paris, 27-28 August 2010.” Endoscopy (2011). PMID: 21425038 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Complications
[177]
Gay G, Delvaux M, Fassler I. “Outcome of capsule endoscopy in determining indication and route for push-and-pull enteroscopy.” Endoscopy (2006). PMID: 16429355 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Endoscopic & Procedural Management, Complications, Special Populations & Prevention
[178]
Matysiak-Budnik T, Coron E, Mosnier JF et al.. “In vivo real-time imaging of human duodenal mucosal structures in celiac disease using endocytoscopy.” Endoscopy (2010). PMID: 20101565 ↗
L4OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Endoscopic & Procedural Management, Special Populations & Prevention
[179]
Kuokkanen M, Myllyniemi M, Vauhkonen M et al.. “A biopsy-based quick test in the diagnosis of duodenal hypolactasia in upper gastrointestinal endoscopy.” Endoscopy (2006). PMID: 16761211 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[180]
Cammarota G, Cuoco L, Cesaro P et al.. “A highly accurate method for monitoring histological recovery in patients with celiac disease on a gluten-free diet using an endoscopic approach that avoids the need for biopsy: a double-center study.” Endoscopy (2007). PMID: 17252460 ↗
L2OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Special Populations & Prevention
[181]
Heine GD, Hadithi M, Groenen MJ et al.. “Double-balloon enteroscopy: indications, diagnostic yield, and complications in a series of 275 patients with suspected small-bowel disease.” Endoscopy (2006). PMID: 16429354 ↗
L4OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs), Endoscopic & Procedural Management, Complications
[182]
Ocagli H, Berti G, Canova C et al.. “Diagnostic accuracy of serological tests for dermatitis herpetiformis: systematic review and Bayesian meta-analysis.” Systematic reviews (2025). PMID: 41327500 ↗
L1SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[183]
Genta RM, Dellon ES, Turner KO. “Non-oesophageal eosinophilic gastrointestinal diseases are undersuspected clinically and underdiagnosed pathologically.” Alimentary pharmacology & therapeutics (2022). PMID: 35546318 ↗
L3OTHERCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[184]
Mandile R, Esposito C, Basile MP et al.. “Advantages of anti-endomysial evaluation in children with low titers of anti-transglutaminase antibodies: A retrospective study.” Journal of pediatric gastroenterology and nutrition (2025). PMID: 41039953 ↗
L3COHORTCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[185]
Xiao YL, Jia YQ, Gu LQ et al.. “Prevalence of Celiac Disease in China Among High-Risk Populations: A Systematic Review and Meta-Analysis.” Journal of digestive diseases (2025). PMID: 41183986 ↗
L1SR_OBSCited in: Diagnosis & Workup (Endoscopy, Imaging & Severity Labs)
[186]
Leffler DA, Kelly CP, Abdallah HZ et al.. “A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge.” The American journal of gastroenterology (2012). PMID: 22825365 ↗
L1RCTCited in: Severity, Staging & Risk Stratification (GI Scores), Acute Management, Long-term & Definitive Medical Management
[187]
Wolf J, Petroff D, Richter T et al.. “Validation of Antibody-Based Strategies for Diagnosis of Pediatric Celiac Disease Without Biopsy.” Gastroenterology (2017). PMID: 28461188 ↗
L3TRIAL_NONRANDOMCited in: Severity, Staging & Risk Stratification (GI Scores)
[188]
Mårild K, Stephansson O, Montgomery S et al.. “Pregnancy outcome and risk of celiac disease in offspring: a nationwide case-control study.” Gastroenterology (2011). PMID: 21995948 ↗
L3CASE_CONTROLCited in: Severity, Staging & Risk Stratification (GI Scores), Special Populations & Prevention
[189]
Andrén Aronsson C, Lee HS, Koletzko S et al.. “Effects of Gluten Intake on Risk of Celiac Disease: A Case-Control Study on a Swedish Birth Cohort.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2015). PMID: 26453955 ↗
L3CASE_CONTROLCited in: Severity, Staging & Risk Stratification (GI Scores)
[190]
Silvester JA, Elli L, Khosla C et al.. “Past, Present, and Future of Noninvasive Tests to Assess Gluten Exposure, Celiac Disease Activity, and End-Organ Damage.” Gastroenterology (2024). PMID: 38670279 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification (GI Scores)
[191]
Anderson RP, Verma R, Schumann M. “A Look Into the Future: Are We Ready for an Approved Therapy in Celiac Disease?” Gastroenterology (2024). PMID: 38355059 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification (GI Scores)
[192]
Rubio-Tapia A, Kyle RA, Kaplan EL et al.. “Increased prevalence and mortality in undiagnosed celiac disease.” Gastroenterology (2009). PMID: 19362553 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores), Special Populations & Prevention
[193]
Meijer CR, Auricchio R, Putter H et al.. “Prediction Models for Celiac Disease Development in Children From High-Risk Families: Data From the PreventCD Cohort.” Gastroenterology (2022). PMID: 35487291 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores)
[194]
Adelman DC, Murray J, Wu TT et al.. “Measuring Change In Small Intestinal Histology In Patients With Celiac Disease.” The American journal of gastroenterology (2018). PMID: 29460921 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification (GI Scores), Prognosis & Natural History
[195]
Coburn S, Trojanowski PJ, Vagadori J et al.. “Development and Validation of a Pediatric Celiac Disease-Specific Quality of Life Measure.” The American journal of gastroenterology (2024). PMID: 39401060 ↗
L4OTHERCited in: Severity, Staging & Risk Stratification (GI Scores)
[196]
Mehtab W, Malhotra A, Upadhyay A et al.. “Development and Validation of a Tool for Assessing Adherence to Gluten-Free Diet in Patients With Celiac Disease.” The American journal of gastroenterology (2024). PMID: 38934507 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores)
[197]
Barret M, Malamut G, Rahmi G et al.. “Diagnostic yield of capsule endoscopy in refractory celiac disease.” The American journal of gastroenterology (2012). PMID: 22964554 ↗
L4OTHERCited in: Severity, Staging & Risk Stratification (GI Scores)
[198]
Shah S, Akbari M, Vanga R et al.. “Patient perception of treatment burden is high in celiac disease compared with other common conditions.” The American journal of gastroenterology (2014). PMID: 24980880 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores)
[199]
Pekki H, Kurppa K, Mäki M et al.. “Predictors and Significance of Incomplete Mucosal Recovery in Celiac Disease After 1 Year on a Gluten-Free Diet.” The American journal of gastroenterology (2015). PMID: 26032154 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification (GI Scores)
[200]
Ravelli A, Villanacci V, Monfredini C et al.. “How patchy is patchy villous atrophy?: distribution pattern of histological lesions in the duodenum of children with celiac disease.” The American journal of gastroenterology (2010). PMID: 20372112 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores)
[201]
Castro FA, Liu X, Försti A et al.. “Increased risk of hepatobiliary cancers after hospitalization for autoimmune disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 24246767 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores)
[202]
Sadr-Azodi O, Sanders DS, Murray JA et al.. “Patients with celiac disease have an increased risk for pancreatitis.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2012). PMID: 22801059 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores)
[203]
Ludvigsson JF, Montgomery SM, Ekbom A. “Risk of pancreatitis in 14,000 individuals with celiac disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2007). PMID: 17702659 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores)
[204]
Leffler DA, Dennis M, Hyett B et al.. “Etiologies and predictors of diagnosis in nonresponsive celiac disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2007). PMID: 17382600 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification (GI Scores), Prognosis & Natural History
[205]
Zanini B, Caselani F, Magni A et al.. “Celiac disease with mild enteropathy is not mild disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2012). PMID: 23022697 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification (GI Scores)
[206]
Leffler DA, Dennis M, Edwards George J et al.. “A validated disease-specific symptom index for adults with celiac disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2009). PMID: 19665584 ↗
L4OTHERCited in: Severity, Staging & Risk Stratification (GI Scores)
[207]
Ludvigsson JF, Elfström P, Broomé U et al.. “Celiac disease and risk of liver disease: a general population-based study.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2006). PMID: 17161656 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores)
[208]
Emilsson L, Wijmenga C, Murray JA et al.. “Autoimmune Disease in First-Degree Relatives and Spouses of Individuals With Celiac Disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2015). PMID: 25645875 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification (GI Scores)
[209]
Seiler CL, Rueda GH, Miranda PM et al.. “Effect of gluten and wheat on symptoms and behaviours in adults with irritable bowel syndrome: a single-centre, randomised, double-blind, sham-controlled crossover trial.” The lancet. Gastroenterology & hepatology (2025). PMID: 40706614 ↗
L1RCTCited in: Severity, Staging & Risk Stratification (GI Scores), Acute Management, Long-term & Definitive Medical Management
[210]
Estevam J, Krutzik P, Vander Tuig J et al.. “Development and validation of a high-parameter mass cytometry workflow to decipher immunomodulatory changes in celiac disease.” Cytometry. Part B, Clinical cytometry (2021). PMID: 33452759 ↗
L4TRIAL_NONRANDOMCited in: Severity, Staging & Risk Stratification (GI Scores)
[211]
Tan IL, Coutinho de Almeida R, Modderman R et al.. “Circulating miRNAs as Potential Biomarkers for Celiac Disease Development.” Frontiers in immunology (2021). PMID: 34950132 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification (GI Scores)
[212]
Delin M, Berglund SK. “Validation of red flags in the workup of children with long-term abdominal pain - A retrospective study.” Acta paediatrica (Oslo, Norway : 1992) (2024). PMID: 38400768 ↗
L3COHORTCited in: Severity, Staging & Risk Stratification (GI Scores)
[213]
Pachisia AV, Kumari A, Mehta S et al.. “Validation of no-biopsy pathway for the diagnosis of celiac disease in Asian adults: a multicenter retrospective study.” Journal of gastroenterology and hepatology (2023). PMID: 38095156 ↗
L3COHORTCited in: Severity, Staging & Risk Stratification (GI Scores)
[214]
Chen J, Sun Y, Fu T et al.. “Risk of incident cardiovascular disease among patients with gastrointestinal disorder: a prospective cohort study of 330 751 individuals.” European heart journal. Quality of care & clinical outcomes (2024). PMID: 37777843 ↗
L2COHORTCited in: Severity, Staging & Risk Stratification (GI Scores)
[215]
Kelly CP, Murray JA, Leffler DA et al.. “TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study.” Gastroenterology (2021). PMID: 33722583 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management
[216]
Kurppa K, Collin P, Viljamaa M et al.. “Diagnosing mild enteropathy celiac disease: a randomized, controlled clinical study.” Gastroenterology (2008). PMID: 19111551 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management
[217]
Murray JA, Syage JA, Wu TT et al.. “Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients With Celiac Disease Exposed to a Gluten Challenge.” Gastroenterology (2022). PMID: 35931103 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management
[218]
Leonard MM, Silvester JA, Leffler D et al.. “Evaluating Responses to Gluten Challenge: A Randomized, Double-Blind, 2-Dose Gluten Challenge Trial.” Gastroenterology (2020). PMID: 33130104 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management
[219]
Lähdeaho ML, Kaukinen K, Laurila K et al.. “Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease.” Gastroenterology (2014). PMID: 24583059 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management
[220]
Hyytinen M, Savilahti E, Virtanen SM et al.. “Avoidance of Cow's Milk-Based Formula for At-Risk Infants Does Not Reduce Development of Celiac Disease: A Randomized Controlled Trial.” Gastroenterology (2017). PMID: 28687275 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management
[221]
Murray JA, Kelly CP, Green PHR et al.. “No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease.” Gastroenterology (2016). PMID: 27864127 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management
[222]
Skodje GI, Sarna VK, Minelle IH et al.. “Fructan, Rather Than Gluten, Induces Symptoms in Patients With Self-Reported Non-Celiac Gluten Sensitivity.” Gastroenterology (2017). PMID: 29102613 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management
[223]
Kurppa K, Paavola A, Collin P et al.. “Benefits of a gluten-free diet for asymptomatic patients with serologic markers of celiac disease.” Gastroenterology (2014). PMID: 24837306 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management
[224]
Sainsbury K, Mullan B, Sharpe L. “A randomized controlled trial of an online intervention to improve gluten-free diet adherence in celiac disease.” The American journal of gastroenterology (2013). PMID: 23458849 ↗
L2RCTCited in: Acute Management, Long-term & Definitive Medical Management
[225]
Francavilla R, Cristofori F, Verzillo L et al.. “Randomized Double-Blind Placebo-Controlled Crossover Trial for the Diagnosis of Non-Celiac Gluten Sensitivity in Children.” The American journal of gastroenterology (2018). PMID: 29380821 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management
[226]
Cartee AK, Choung RS, King KS et al.. “Plasma IL-2 and Symptoms Response after Acute Gluten Exposure in Subjects With Celiac Disease or Nonceliac Gluten Sensitivity.” The American journal of gastroenterology (2022). PMID: 34797778 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management
[227]
Johansen A, Sandve GKF, Maxwell JR et al.. “Biopsy Proteome Score Performs Well as an Effect Measure in a Gluten Challenge Trial of Celiac Disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 39209203 ↗
L2RCTCited in: Acute Management, Long-term & Definitive Medical Management
[228]
Greco L, Gobbetti M, Auricchio R et al.. “Safety for patients with celiac disease of baked goods made of wheat flour hydrolyzed during food processing.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2010). PMID: 20951830 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management
[229]
van Megen F, Skodje GI, Lergenmuller S et al.. “A Low FODMAP Diet Reduces Symptoms in Treated Celiac Patients With Ongoing Symptoms-A Randomized Controlled Trial.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2022). PMID: 35051648 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management
[230]
Begtrup LM, Engsbro AL, Kjeldsen J et al.. “A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 23357491 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management
[231]
Wolf RL, Green PHR, Lee AR et al.. “Benefits From and Barriers to Portable Detection of Gluten, Based on a Randomized Pilot Trial of Patients With Celiac Disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2019). PMID: 30885882 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management
[232]
Satherley RM, Francios-Walcott R, Tallentire H et al.. “Psychological intervention for parents of children with celiac disease: A pilot and feasibility randomized controlled trial.” Journal of pediatric gastroenterology and nutrition (2026). PMID: 41589456 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management, Special Populations & Prevention
[233]
Bentley D, Mannino M, Manchester M et al.. “A randomized, double-blind, placebo-controlled, multiple dose, parallel study to investigate the effects of a cathepsin S inhibitor in celiac disease.” Clinical and translational science (2025). PMID: 39739628 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management, Prognosis & Natural History
[234]
Dotsenko V, Tewes B, Hils M et al.. “Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease.” Nature immunology (2024). PMID: 38914866 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management
[235]
Nikoloudaki O, Celano G, Polo A et al.. “Novel probiotic preparation with in vivo gluten-degrading activity and potential modulatory effects on the gut microbiota.” Microbiology spectrum (2024). PMID: 38860826 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management
[236]
Stefanolo JP, Segura V, Grizzuti M et al.. “Effect of Aspergillus niger prolyl endopeptidase in patients with celiac disease on a long-term gluten-free diet.” World journal of gastroenterology (2024). PMID: 38617446 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management
[237]
Hurych J, Oscarsson E, Håkanson Å et al.. “Effects of Lactiplantibacillus plantarum and Lacticaseibacillus paracasei supplementation on the single-cell fecal parasitome in children with celiac disease autoimmunity: a randomized, double-blind placebo-controlled clinical trial.” Parasites & vectors (2023). PMID: 37946274 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management
[238]
Isola J, Mäki M, Hils M et al.. “The Oral Transglutaminase 2 Inhibitor ZED1227 Accumulates in the Villous Enterocytes in Celiac Disease Patients during Gluten Challenge and Drug Treatment.” International journal of molecular sciences (2023). PMID: 37445994 ↗
L2RCTCited in: Acute Management, Long-term & Definitive Medical Management
[239]
Lionetti E, Dominijanni V, Iasevoli M et al.. “Effects of the supplementation with a multispecies probiotic on clinical and laboratory recovery of children with newly diagnosed celiac disease: A randomized, placebo-controlled trial.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2023). PMID: 37164895 ↗
L1RCTCited in: Acute Management, Long-term & Definitive Medical Management
[240]
Banegas M, Flores-Marin D, Naskar N et al.. “Gastrointestinal and Extraintestinal Symptoms Among Subjects With Celiac Disease Undergoing a Dose-Specified Gluten Challenge: A Systematic Review and Meta-Analysis.” The American journal of gastroenterology (2025). PMID: 40298233 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management, Prognosis & Natural History
[241]
Freitag TL, Podojil JR, Pearson RM et al.. “Gliadin Nanoparticles Induce Immune Tolerance to Gliadin in Mouse Models of Celiac Disease.” Gastroenterology (2020). PMID: 32032584 ↗
L4OTHERCited in: Long-term & Definitive Medical Management
[242]
Verdu EF. “Differences in intestinal microbial composition in children with IBS-what does it all mean?” The American journal of gastroenterology (2012). PMID: 23160293 ↗
L5OTHERCited in: Long-term & Definitive Medical Management
[243]
Korpimäki S, Kaukinen K, Collin P et al.. “Gluten-sensitive hypertransaminasemia in celiac disease: an infrequent and often subclinical finding.” The American journal of gastroenterology (2011). PMID: 21502996 ↗
L3OTHERCited in: Long-term & Definitive Medical Management
[244]
Adriaanse MP, Leffler DA, Kelly CP et al.. “Serum I-FABP Detects Gluten Responsiveness in Adult Celiac Disease Patients on a Short-Term Gluten Challenge.” The American journal of gastroenterology (2016). PMID: 27185075 ↗
L4OTHERCited in: Long-term & Definitive Medical Management
[245]
Papadia C, Sherwood RA, Kalantzis C et al.. “Plasma citrulline concentration: a reliable marker of small bowel absorptive capacity independent of intestinal inflammation.” The American journal of gastroenterology (2007). PMID: 17459021 ↗
L4OTHERCited in: Long-term & Definitive Medical Management
[246]
Lau MS, Mooney PD, White WL et al.. “The Role of an IgA/IgG-Deamidated Gliadin Peptide Point-of-Care Test in Predicting Persistent Villous Atrophy in Patients With Celiac Disease on a Gluten-Free Diet.” The American journal of gastroenterology (2017). PMID: 29016564 ↗
L2OTHERCited in: Long-term & Definitive Medical Management
[247]
Stoven S, Murray JA, Marietta E. “Celiac disease: advances in treatment via gluten modification.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2012). PMID: 22728383 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Medical Management
[248]
Green PH, Yang J, Cheng J et al.. “An association between microscopic colitis and celiac disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2009). PMID: 19631283 ↗
L3OTHERCited in: Long-term & Definitive Medical Management
[249]
Dieckman T, Schumann M, Beaumont H et al.. “Enduring Clinical Remission in Refractory Celiac Disease Type II With Tofacitinib: An Open-Label Clinical Study.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2024). PMID: 38821313 ↗
L4OTHERCited in: Long-term & Definitive Medical Management
[250]
Akram S, Murray JA, Pardi DS et al.. “Adult autoimmune enteropathy: Mayo Clinic Rochester experience.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2007). PMID: 17683994 ↗
L4OTHERCited in: Long-term & Definitive Medical Management
[251]
Rubio-Tapia A, Talley NJ, Gurudu SR et al.. “Gluten-free diet and steroid treatment are effective therapy for most patients with collagenous sprue.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2010). PMID: 20060071 ↗
L4OTHERCited in: Long-term & Definitive Medical Management
[252]
Therrien A, Silvester JA, Leffler DA et al.. “Efficacy of Enteric-Release Oral Budesonide in Treatment of Acute Reactions to Gluten in Patients With Celiac Disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2019). PMID: 30905717 ↗
L5OTHERCited in: Long-term & Definitive Medical Management
[253]
Ladabaum U, Boyd E, Zhao WK et al.. “Diagnosis, comorbidities, and management of irritable bowel syndrome in patients in a large health maintenance organization.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2011). PMID: 21871250 ↗
L3OTHERCited in: Long-term & Definitive Medical Management
[254]
Falcomer AL, de Lima BR, Farage P et al.. “Enhancing life with celiac disease: unveiling effective tools for assessing health-related quality of life.” Frontiers in immunology (2024). PMID: 38742113 ↗
L1SR_OBSCited in: Long-term & Definitive Medical Management
[255]
Cammarota G, Cesaro P, Cazzato A et al.. “Optimal band imaging system: a new tool for enhancing the duodenal villous pattern in celiac disease.” Gastrointestinal endoscopy (2008). PMID: 18547574 ↗
L2TRIAL_NONRANDOMCited in: Endoscopic & Procedural Management, Special Populations & Prevention
[256]
Lebreton C, Ménard S, Abed J et al.. “Interactions among secretory immunoglobulin A, CD71, and transglutaminase-2 affect permeability of intestinal epithelial cells to gliadin peptides.” Gastroenterology (2012). PMID: 22750506 ↗
L4OTHERCited in: Endoscopic & Procedural Management
[257]
Leong RW, Nguyen NQ, Meredith CG et al.. “In vivo confocal endomicroscopy in the diagnosis and evaluation of celiac disease.” Gastroenterology (2008). PMID: 18848944 ↗
L2OTHERCited in: Endoscopic & Procedural Management
[258]
Di Sabatino A, Giuffrida P, Vanoli A et al.. “Increase in neuroendocrine cells in the duodenal mucosa of patients with refractory celiac disease.” The American journal of gastroenterology (2014). PMID: 24394748 ↗
L3OTHERCited in: Endoscopic & Procedural Management
[259]
Rondonotti E, Spada C, Cave D et al.. “Video capsule enteroscopy in the diagnosis of celiac disease: a multicenter study.” The American journal of gastroenterology (2007). PMID: 17459022 ↗
L2OTHERCited in: Endoscopic & Procedural Management
[260]
Hadithi M, Al-toma A, Oudejans J et al.. “The value of double-balloon enteroscopy in patients with refractory celiac disease.” The American journal of gastroenterology (2007). PMID: 17378908 ↗
L2OTHERCited in: Endoscopic & Procedural Management
[261]
Chong AK, Chin BW, Meredith CG. “Clinically significant small-bowel pathology identified by double-balloon enteroscopy but missed by capsule endoscopy.” Gastrointestinal endoscopy (2006). PMID: 16923502 ↗
L4CASE_REPORTCited in: Endoscopic & Procedural Management, Complications
[262]
Robert ME, Crowe SE, Burgart L et al.. “Statement on Best Practices in the Use of Pathology as a Diagnostic Tool for Celiac Disease: A Guide for Clinicians and Pathologists.” The American journal of surgical pathology (2018). PMID: 29923907 ↗
L1GUIDELINECited in: Endoscopic & Procedural Management
[263]
Stoven SA, Choung RS, Rubio-Tapia A et al.. “Analysis of Biopsies From Duodenal Bulbs of All Endoscopy Patients Increases Detection of Abnormalities but has a Minimal Effect on Diagnosis of Celiac Disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2016). PMID: 26965842 ↗
L3OTHERCited in: Endoscopic & Procedural Management
[264]
Valitutti F, Di Nardo G, Barbato M et al.. “Mapping histologic patchiness of celiac disease by push enteroscopy.” Gastrointestinal endoscopy (2013). PMID: 23886355 ↗
L2OTHERCited in: Endoscopic & Procedural Management, Special Populations & Prevention
[265]
Darbari A, Kalloo AN, Cuffari C. “Diagnostic yield, safety, and efficacy of push enteroscopy in pediatrics.” Gastrointestinal endoscopy (2006). PMID: 16860073 ↗
L3OTHERCited in: Endoscopic & Procedural Management, Complications
[266]
Mangiavillano B, Masci E, Parma B et al.. “Bulb biopsies for the diagnosis of celiac disease in pediatric patients.” Gastrointestinal endoscopy (2010). PMID: 20630510 ↗
L2OTHERCited in: Endoscopic & Procedural Management
[267]
Zambelli A, Villanacci V, Buscarini E et al.. “Confocal laser endomicroscopy in celiac disease: description of findings in two cases.” Endoscopy (2007). PMID: 17926241 ↗
L4OTHERCited in: Endoscopic & Procedural Management, Special Populations & Prevention
[268]
Zubarik R, Ganguly E, Nathan M et al.. “Celiac disease detection in hypothyroid patients requiring elevated thyroid supplementation: A prospective cohort study.” European journal of internal medicine (2015). PMID: 26423749 ↗
L2TRIAL_NONRANDOMCited in: Endoscopic & Procedural Management
[269]
Valitutti F, Oliva S, Iorfida D et al.. “Narrow band imaging combined with water immersion technique in the diagnosis of celiac disease.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2014). PMID: 25224697 ↗
L2TRIAL_NONRANDOMCited in: Endoscopic & Procedural Management
[270]
Gu Z, Wang Y, Lin K et al.. “Magnetically Controlled Capsule Endoscopy in Children: A Single-center, Retrospective Cohort Study.” Journal of pediatric gastroenterology and nutrition (2019). PMID: 30747810 ↗
L3COHORTCited in: Endoscopic & Procedural Management
[271]
Ancona S, Malerba F, Medina F et al.. “Adherence to guidelines, pitfalls, and emerging technologies in endoscopic practice for celiac disease: a nationwide SIGENP survey.” European journal of pediatrics (2026). PMID: 41807635 ↗
L2OTHERCited in: Endoscopic & Procedural Management
[272]
Bowman CJ, Stibor DM, Sun X et al.. “A20's linear ubiquitin-binding motif restrains pathogenic activation of Th17 cells and IL-22-driven enteritis.” The Journal of clinical investigation (2025). PMID: 40892518 ↗
L4OTHERCited in: Endoscopic & Procedural Management
[273]
Nandi N, Topa M, Rimondi A et al.. “Computer aided villi morphometric quantification in video-capsule enteroscopy: A newly developed software to quantify small bowel atrophy.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2024). PMID: 39358114 ↗
L3OTHERCited in: Endoscopic & Procedural Management
[274]
Harold KM, MacCuaig WM, Holter-Charkabarty J et al.. “Advances in Imaging of Inflammation, Fibrosis, and Cancer in the Gastrointestinal Tract.” International journal of molecular sciences (2022). PMID: 36555749 ↗
L5REVIEW_NARRATIVECited in: Endoscopic & Procedural Management
[275]
Mandile R, Discepolo V, Auricchio R et al.. “From Autoimmunity to Intestinal Tissue Damage: Insights From Potential Celiac Disease as a Paradigm of Disease Progression.” Gastroenterology (2026). PMID: 41881136 ↗
L5REVIEW_NARRATIVECited in: Complications, Prognosis & Natural History
[276]
Liu E, Dong F, Barón AE et al.. “High Incidence of Celiac Disease in a Long-term Study of Adolescents With Susceptibility Genotypes.” Gastroenterology (2017). PMID: 28188747 ↗
L2OTHERCited in: Complications
[277]
Santacroce G, Vanoli A, Aronico N et al.. “Different Survival Outcomes of Small Bowel Adenocarcinomas and T-Cell Lymphomas Associated With Celiac Disease.” The American journal of gastroenterology (2025). PMID: 40471829 ↗
L3OTHERCited in: Complications, Prognosis & Natural History, Special Populations & Prevention
[278]
Kårhus LL, Skaaby T, Petersen J et al.. “Long-term Consequences of Undiagnosed Celiac Seropositivity.” The American journal of gastroenterology (2020). PMID: 32558687 ↗
L2OTHERCited in: Complications, Prognosis & Natural History, Special Populations & Prevention
[279]
Leighton JA. “The role of endoscopic imaging of the small bowel in clinical practice.” The American journal of gastroenterology (2010). PMID: 20978483 ↗
L5REVIEW_NARRATIVECited in: Complications
[280]
Volta U, Caio G, Giancola F et al.. “Features and Progression of Potential Celiac Disease in Adults.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2015). PMID: 26538207 ↗
L2OTHERCited in: Complications, Special Populations & Prevention
[281]
Mant MJ, Bain VG, Maguire CG et al.. “Prevalence of occult gastrointestinal bleeding in celiac disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2006). PMID: 16616349 ↗
L3OTHERCited in: Complications
[282]
Malamut G, Meresse B, Kaltenbach S et al.. “Small intestinal CD4+ T-cell lymphoma is a heterogenous entity with common pathology features.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2013). PMID: 24316103 ↗
L4OTHERCited in: Complications
[283]
Williams JJ, Kaplan GG, Makhija S et al.. “Microscopic colitis-defining incidence rates and risk factors: a population-based study.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2008). PMID: 18166476 ↗
L2OTHERCited in: Complications
[284]
Stefanolo JP, Zingone F, Gizzi C et al.. “Upper gastrointestinal endoscopic findings in celiac disease at diagnosis: A multicenter international retrospective study.” World journal of gastroenterology (2022). PMID: 36483156 ↗
L3COHORTCited in: Complications
[285]
Reynolds C, Esrailian E, Hommes D. “Quality Improvement in Gastroenterology: A Systematic Review of Practical Interventions for Clinicians.” Digestive diseases and sciences (2018). PMID: 30014225 ↗
L2SR_OBSCited in: Complications
[286]
Gheshlagh RG, Rezaei H, Goli M et al.. “Prevalence of celiac disease in Iranian patients with type 1 diabetes: A systematic review and meta-analysis.” Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology (2020). PMID: 33263176 ↗
L1SR_OBSCited in: Complications
[287]
Alsaadi D, Shah NJ, Charabaty A et al.. “A case of checkpoint inhibitor-induced celiac disease.” Journal for immunotherapy of cancer (2019). PMID: 31383006 ↗
L4CASE_REPORTCited in: Complications
[288]
Yu C, Huang Y, Han B et al.. “Role of PANoptosis in intestinal diseases and its therapeutic implications.” Journal of molecular medicine (Berlin, Germany) (2026). PMID: 42174223 ↗
L5REVIEW_NARRATIVECited in: Complications
[289]
Singh P, Lee A, Sheth NM et al.. “Chronic, Noninfectious Diarrhea: A Review.” JAMA (2026). PMID: 41770539 ↗
L5REVIEW_NARRATIVECited in: Complications
[290]
Bakhtiari S, Asri N, Masotti A et al.. “Essential amino acids in celiac disease: key roles in immunogenicity, pathogenesis, and therapeutic approaches.” Critical reviews in clinical laboratory sciences (2025). PMID: 40910339 ↗
L5REVIEW_NARRATIVECited in: Complications
[291]
Malamut G, Soderquist CR, Bhagat G et al.. “Advances in Nonresponsive and Refractory Celiac Disease.” Gastroenterology (2024). PMID: 38556189 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History
[292]
Celdir MG, Choung RS, Rostamkolaei SK et al.. “Reproductive Characteristics and Pregnancy Outcomes in Hidden Celiac Disease Autoimmunity.” The American journal of gastroenterology (2021). PMID: 33560653 ↗
L3OTHERCited in: Prognosis & Natural History, Special Populations & Prevention
[293]
Tosco A, Salvati VM, Auricchio R et al.. “Natural history of potential celiac disease in children.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2010). PMID: 20851213 ↗
L2OTHERCited in: Prognosis & Natural History
[294]
Ford A, Chatterjee A, Lyu R et al.. “Increased Risk of Hospitalization in Celiac Disease With COVID-19 Infection Is Mitigated by Vaccination.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2023). PMID: 36806628 ↗
L3OTHERCited in: Prognosis & Natural History
[295]
Faye AS, Polubriaginof F, Green PHR et al.. “Low Rates of Screening for Celiac Disease Among Family Members.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2018). PMID: 29913278 ↗
L3OTHERCited in: Prognosis & Natural History, Special Populations & Prevention
[296]
Webster J, Vajravelu ME, Choi C et al.. “Prevalence of and Risk Factors for Low Bone Mineral Density in Children With Celiac Disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2018). PMID: 31230659 ↗
L3OTHERCited in: Prognosis & Natural History
[297]
Albasha Hejazi AM, Abd-ElGawad M, Gadelmawla AF et al.. “Efficacy of latiglutenase in treating celiac disease: a systematic review and meta-analysis of randomized controlled trials.” Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology (2025). PMID: 40582901 ↗
L1SR_MA_RCTCited in: Prognosis & Natural History
[298]
Reijonen JK, Tihtonen KMH, Luukkaala TH et al.. “Gluten-free diet during pregnancy and pregnancy outcome: A retrospective cohort study.” International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2025). PMID: 39791270 ↗
L3COHORTCited in: Prognosis & Natural History
[299]
Vécsei AK, Graf UB, Vogelsang H. “Follow-up of adult celiac patients: which noninvasive test reflects mucosal status most reliably?1.” Endoscopy (2009). PMID: 19214890 ↗
L2RCTCited in: Special Populations & Prevention
[300]
Gonzalez S, Gupta A, Cheng J et al.. “Prospective study of the role of duodenal bulb biopsies in the diagnosis of celiac disease.” Gastrointestinal endoscopy (2010). PMID: 20883853 ↗
L3COHORTCited in: Special Populations & Prevention
[301]
Heijdra Suasnabar J, Meijer CR, Smit L et al.. “Long-Term Cost-Effectiveness of Case Finding and Mass Screening for Celiac Disease in Children.” Gastroenterology (2024). PMID: 39084268 ↗
L2OTHERCited in: Special Populations & Prevention
[302]
Hardy MY, Girardin A, Pizzey C et al.. “Consistency in polyclonal T-cell responses to gluten between children and adults with celiac disease.” Gastroenterology (2015). PMID: 26226573 ↗
L4OTHERCited in: Special Populations & Prevention
[303]
Croall ID, Sanders DS, Hadjivassiliou M et al.. “Cognitive Deficit and White Matter Changes in Persons With Celiac Disease: A Population-Based Study.” Gastroenterology (2020). PMID: 32088203 ↗
L3OTHERCited in: Special Populations & Prevention
[304]
Moreno ML, Cebolla Á, Muñoz-Suano A et al.. “Detection of gluten immunogenic peptides in the urine of patients with coeliac disease reveals transgressions in the gluten-free diet and incomplete mucosal healing.” Gut (2015). PMID: 26608460 ↗
L4OTHERCited in: Special Populations & Prevention
[305]
Stahl M, Li Q, Lynch K et al.. “Incidence of Pediatric Celiac Disease Varies by Region.” The American journal of gastroenterology (2022). PMID: 36219178 ↗
L2OTHERCited in: Special Populations & Prevention
[306]
Stahl MG, Geno Rasmussen C, Dong F et al.. “Mass Screening for Celiac Disease: The Autoimmunity Screening for Kids Study.” The American journal of gastroenterology (2021). PMID: 32701732 ↗
L2OTHERCited in: Special Populations & Prevention
[307]
Pucinischi V, Kenyon V, Montuori M et al.. “Elevation of tTG-IgA Antibodies in a Prospective Cohort of Children at Risk of Celiac Disease: Insights From the CDGEMM Cohort.” The American journal of gastroenterology (2025). PMID: 41020645 ↗
L2OTHERCited in: Special Populations & Prevention
[308]
Gould MJ, Mahmud FH, Clarke ABM et al.. “Accuracy of Screening Tests for Celiac Disease in Asymptomatic Patients With Type 1 Diabetes.” The American journal of gastroenterology (2021). PMID: 33852450 ↗
L2OTHERCited in: Special Populations & Prevention
[309]
Smyth DJ, Plagnol V, Walker NM et al.. “Shared and distinct genetic variants in type 1 diabetes and celiac disease.” The New England journal of medicine (2008). PMID: 19073967 ↗
L3OTHERCited in: Special Populations & Prevention
[310]
Wang Y, Cao Y, Lebwohl B et al.. “Gluten Intake and Risk of Digestive System Cancers in 3 Large Prospective Cohort Studies.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2021). PMID: 34800737 ↗
L2OTHERCited in: Special Populations & Prevention
[311]
Lecleire S, Di Fiore F, Antonietti M et al.. “Endoscopic markers of villous atrophy are not useful for the detection of celiac disease in patients with dyspeptic symptoms.” Endoscopy (2006). PMID: 16761210 ↗
L3OTHERCited in: Special Populations & Prevention
[312]
Villafuerte-Galvez J, Vanga RR, Dennis M et al.. “Factors governing long-term adherence to a gluten-free diet in adult patients with coeliac disease.” Alimentary pharmacology & therapeutics (2015). PMID: 26206401 ↗
L4OTHERCited in: Special Populations & Prevention
[313]
Nilsson N, Salmi T, Viikki M et al.. “Cohort study of neurological and psychiatric morbidity in dermatitis herpetiformis and celiac disease.” Scandinavian journal of gastroenterology (2026). PMID: 41761874 ↗
L3COHORTCited in: Special Populations & Prevention
[314]
Tetik Dinçer B, Urgancı N, Koç A et al.. “Association of endocrine autoantibodies (anti-TPO, anti-GAD, anti-insulin) with histopathological severity in pediatric Celiac disease: a retrospective cohort study.” BMC pediatrics (2025). PMID: 41430660 ↗
L3COHORTCited in: Special Populations & Prevention
[315]
Peresztegi MZ, Szakács Z, Farkas N et al.. “Hepatic Steatosis and Diet in Adult Celiac Disease: A Cross-Sectional Study.” Nutrients (2025). PMID: 41305627 ↗
L4RCTCited in: Special Populations & Prevention

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

Definition, Classification & Nomenclature

Clinical Classifications and Variants

Histologic Grading (Marsh Classification)

Pathophysiology & Mechanism

The Pathogenic Cascade

Genetic and Environmental Susceptibility

Systemic and Extra-Intestinal Mechanisms

Comparative Pathogenesis of Gluten-Related Disorders

Epidemiology, Etiology & Risk Factors

Demographic Distribution and Temporal Trends

Etiology and Risk Factors

Associated Comorbidities

Risk Factor Summary

Clinical Presentation

Presenting Symptoms

Physical Examination and Systemic Findings

Phenotypic Variants

Red Flags and Atypical Presentations

Atypical and Mimicking Presentations

Diagnosis & Workup

Laboratory Studies

Gold-Standard Test: Duodenal Biopsy

Endoscopic and Imaging Modalities

Diagnostic Algorithm

Controversies and Guideline Disagreement

Severity, Staging & Risk Stratification

Histological Severity and Morphometry

Prognostic Scoring and Risk Stratification

Disease Activity and Symptom Indices

Complication-Based Risk Stratification

Acute Management

Step 1: Initial Assessment and Symptom Stratification

Step 2: First-Line Intervention

Step 3: Adjunctive and Investigational Pharmacotherapy

Step 4: Monitoring and Recovery

Step 5: Transition to Long-Term Maintenance

Drug / Modality Comparison Table

Dosing Table

What NOT to Do

Controversies and Guideline Disagreement

Long-term & Definitive Medical Management

Step 1: Implementation of the Gluten-Free Diet

Step 2: Management of Persistent Symptoms

Step 3: Adjunctive and Experimental Pharmacotherapy

Step 4: Management of Refractory Celiac Disease (RCD)

Drug and Modality Comparison Table

Dosing Table

What NOT to Do

Controversies and Guideline Disagreement

Endoscopic and Procedural Management

Step 1: Optimized Mucosal Sampling

Step 2: Advanced Endoscopic Imaging for VA Identification

Step 3: Small-Bowel Evaluation in Non-Responsive Disease

Step 4: Monitoring and Longitudinal Assessment

Modality Comparison for Small-Bowel Assessment

What NOT to Do

Controversies and Guideline Disagreement

Complications

Small Bowel Malignancies

Gastrointestinal Sequelae

Systemic and Extra-intestinal Complications

Surveillance and Management of Complications

Prognosis & Natural History

Untreated and Undiagnosed Trajectories

Treated Trajectory and Remission Dynamics

Predictors of Outcome and Complications

Potential Celiac Disease (PCD) Progression

Special Populations & Prevention

Pediatrics

Pregnancy

Elderly

Immunocompromised and Comorbid States

Step 2: of Persistent Symptoms

Sequelae

Surveillance and of Complications